

James Edward Haddow, M.D.

Department of Pathology and Laboratory Medicine
Women and Infants Hospital of Rhode Island

Business or Mailing Address: 35 Main Street, Unit #1, Windham, ME 04062
Business Telephone Number: 207-894-6610
Business Fax Number: 207-892-8620
Electronic Mail Address: jhaddow@ipmms.org or jhaddow@wihri.org

EDUCATION

Undergraduate	Harvard University, English, B.A., 1957
Medical School	Tufts University, M.D., 1957-1961

POSTGRADUATE TRAINING

Residency	Maine Medical Center, Portland, ME, rotating internship, 1961-1962 Boston City Hospital, Boston, MA, Pediatrics, 1962-1964
Fellowship	Boston City Hospital, Boston, MA, Metabolism and Endocrinology, Dept. of Pediatrics, 1966-1967

POSTGRADUATE HONORS AND AWARDS:

Visiting Scientist	1985
Department of Environmental and Preventive Medicine Medical College of St. Bartholomew's Hospital London, England	
Libra Distinguished Professor In Applied Immunology, University of Southern Maine	1997-1998
Honorary Research Fellow, Wolfson Institute of Preventive Medicine London, England	2004-present

MILITARY SERVICE:

Captain, Pediatrician, U.S. Army Medical Corps, Fort Campbell, KY	1964-1966
---	-----------

PROFESSIONAL LICENSES AND BOARD CERTIFICATION:

American Board of Pediatrics	1966
Board of Registration of Medicine, Commonwealth of Massachusetts	1966-74
Board of Registration of Medicine, State of Maine - #7703	July 17, 1974-present

ACADEMIC APPOINTMENTS:

1967-1969 Instructor in Pediatrics, Boston University School of Medicine
1967-1974 Clinical Instructor in Pediatrics, Harvard Medical School
1969-1972 Assistant Professor of Pediatrics, Boston University School of Medicine
1970-1974 Director, Medical Student Teaching in Pediatrics, Boston University School of Medicine
1972-1974 Associate Professor in Pediatrics, Boston University School of Medicine
1974-1980 Associate Clinical Professor of Pediatrics, Tufts University School of Medicine
1980 Lecturer, University of New England School of Osteopathy
1981-1993 Associate Clinical Professor of Pediatrics, University of Vermont School of Medicine
1988-Present Adjunct Professor, Department of Applied Medical Science, University of Southern Maine
1993-Present Clinical Professor of Pediatrics, University of Vermont School of Medicine
2005-Present Professor of Pathology and Laboratory Medicine (Research), The Warren Alpert Medical School of Brown University, Providence, Rhode Island

HOSPITAL APPOINTMENTS:

1966-1967 Fellow, Pediatric Endocrinology/Metabolism
1967-1971 Assistant Director, Pediatric Clinical Center, Boston City Hospital
1968-1971 Assistant Visiting Physician, Boston City Hospital
1971-1974 Director, Pediatric Metabolism and Endocrinology, Boston City Hospital
1971-1974 Visiting Physician, Boston City Hospital
1972-1974 Associate Staff, Kennedy Memorial Hospital, Brighton, Massachusetts
1974-Present Associate Medical Staff, Maine Medical Center, Department of Research with privileges in Pediatrics
1974-1977 Associate Director, Rheumatic Disease Laboratory, Maine Medical Center
1977-2004 Vice President/Medical Director, Foundation for Blood Research, Scarborough, Maine
2004-Present Co-Director, Division of Medical Screening & Special Testing, Department of Pathology and Laboratory Medicine, Women & Infants Hospital, Providence, Rhode Island

OTHER APPOINTMENTS:

1973-1974 Trustee, Southeastern Mass University
1976-1980 New England Amniocentesis Group
1976 Trustee, Center Memorial Clinic, Steep Falls, Maine
1976-1983 Scientific Advisor - Southern Maine Chapter, March of Dimes
1977 First Scarborough Conference, Planner, Co-Chairman
1978 Second Scarborough Conference, Planner, Co-Chairman
1978-1997 Chair, Quality Control Committee, New England Regional Genetics Group (NERGG)
1979-1981 NCCLS Committee to Establish Alpha-Fetoprotein Standards
1980 Conference on Maternal Serum Alpha-Fetoprotein, National Center for Health Care Technology, Director, Planning Committee, and Conference Chairman
1980 Third Scarborough Conference, Planner, Co-Chairman
1983 Member at large, Board of Directors, American Cancer Society (Maine Division)
1984 Fourth Scarborough Conference, Co-Planner, Co-Chairman (Public Health Implications of the Low-Tar Cigarette Policy)
1985-2004 Annual Short Courses in Screening for Major Fetal Disorders, Planner, Co-Chairman
1985 American Society for Human Genetics -- Alpha-fetoprotein Subcommittee
1985-2008 Editorial Board, *Prenatal Diagnosis*
1986 Primary CAD Prevention: Current Approaches to Screening, Management, and Education, Co-Planner
1988 Fifth Scarborough Conference, Co-Planner, Co-Chairman

1988-1991 Co-Chair, AFP QC Committee, Council of Regional Networks for Genetics Services
 1991 Member, University of Southern Maine School of Applied Science Advisory Council
 1991-1993 Chair, Quality Control Committee, Council of Regional Networks for Genetics Services (CORN)
 1994-Present Associate Editor, *Journal of Medical Screening*
 1998 Sixth Scarborough Conference, Planner, Co-Chairman (Issues in Implementing Prenatal Screening for Cystic Fibrosis)
 2003 Member, National Center for Research Resources Special Emphasis Panel, National Center for Research Resources ZRR1 SEPA-4 (01)
 2004-2011 Expert Advisor, Evaluation of Genomic Applications in Practice and Prevention (EGAPP), Centers for Disease Control (CDC)
 2004-2007 Member, Data and Safety Monitoring Board, (for clinical trial entitled *Pilot Trial of Thyroid Hormone in Prematures*), National Institute of Neurological Diseases and Stroke, National Institutes of Health
 2005-Present Advisory Board, Clinical Genetics Institute, Intermountain Health Care, Salt Lake City, Utah

HOSPITAL COMMITTEES:

1976-1977 IRB, Maine Medical Center
 1978-2004 IRB, Foundation for Blood Research

UNIVERSITY COMMITTEES:

None

MEMBERSHIP IN SOCIETIES:

1974-Present Society for Pediatric Research
 1974-1980 Maine Chapter, American Academy of Pediatrics
 1978-1997 New England Regional Genetics Group, Member Steering Committee, Member, 1979 - 1997
 1978 Maine Association for Human Genetics - Vice President
 1979 Maine Association for Human Genetics - President
 1991-1995 New England Pediatric Society
 1997-Present American College of Medical Genetics
 2001-Present Medical Screening Society; founding co-director
 2008-Present American Thyroid Association
 2012-Present Endocrine Society

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS:

1. Engel E, Haddow JE, Lewis JF, Tipton RE, Overall JC, McGee BJ, Levrat OH, Engel-de-montmollin M: Three unusual trisomic patterns in children. Triple X plus triple E-triple X mosaic: normal XY-D trisomy mosaic; partial trisomy with E translocation. *Am J Dis Child*, 113(3):322-328, 1967. PMID: 6019450.
2. Young LM, Haddow JE, Klein JO: Relapse following ampicillin treatment of acute Hemophilus influenzae meningitis. *Pediatrics*, 41(2):516-518, 1968. PMID: 5300101.
3. Klein JO, Haddow JE, Young LM: Ampicillin dosage. *Pediatrics*, 42(1):212, 1968. PMID: 5657686.
4. Klein R, Haddow JE: Trace elements in health and disease. *Practitioner*, 201(202):314-323, 1968. PMID: 5667886.
5. Klein R, Haddow JE, Kind C, Cockburn P: Effect of cold on muscle potentials and electrolytes. *Metabolism*, 17(12):1094-1103, 1968. PMID: 5703476.
6. McFadden SW, Haddow JE: Coma produced by topical application of isopropanol. *Pediatrics*, 43(4):622-623, 1969. PMID: 5777081.

7. Gall DG, Haddow JE: Effects of acute hypernatremia. *Lancet*, i(7598):783, 1969. PMID: 4180870.
8. Bonacci A, Haddow JE: Hazard in the nursery. *N Engl J Med*, 282(11):633, 1970. PMID: 5461098.
9. Klein R, Haddow JE: Arterial-venous potassium differences in paramyotonia. *Pediatr Res*, 4(3):286-294, 1970. PMID: 5423162.
10. Haddow JE, Klein R: Cardiac glycoside effects on rat skeletal muscle potentials and electrolytes. *Proc Soc Exp Biol Med*, 133(1):138-143, 1970. PMID: 5412327.
11. Haddow JE, Shapiro SR, Gall DG: Congenital sensory neuropathy in siblings. *Pediatrics*, 45(4):651-655, 1970. PMID: 4191331.
12. Haddow JE, Gall DG: Occult helminth infection with appearance of splenic and lung calcifications. *Am J Dis Child*, 120(6):555-556, 1970. PMID: 5481908.
13. Cranley WR, Haddow JE: Methadone overdosage in children. *N Engl J Med*, 284(14):792, 1971. PMID: 5548040.
14. Haddow JE, Sher N, Gall DG, Green D: Streptococcal wound infection with evidence of widespread tissue involvement. *Pediatrics*, 48(3):458-462, 1971. PMID: 5094350.
15. Gall G, Vaitukaitis J, Haddow JE, Klein R: Erythrocyte Na flux in a patient with Bartter's syndrome. *J Clin Endocrinol Metab*, 32(4):562-567, 1971. PMID: 5547273.
16. Cranley WR, Haddow JE: Methadone overdosage in children. *N Engl J Med*, 284(14):792, 1971. PMID: 5548040.
17. Klein R, Haddow JE, DeLuca C: Familial congenital disorder resembling stiff-man syndrome. *Am J Dis Child*, 124(5):730-731, 1972. PMID: 4508100.
18. Haddow JE, Marshall PC: Increased stool mercury excretion in the rat: the effect of spironolactone. *Proc Soc Exp Biol Med*, 140(2):707-709, 1972. PMID: 5037611.
19. Haddow JE, Fish CA, Marshall PC, Lester R: Biliary excretion of mercury enhanced by spironolactone. *Gastroenterology*, 63(6):1053-1058, 1972. PMID: 4639360.
20. Feldman RG, Haddow JE, Kopito L, Schwachman H: Altered peripheral nerve conduction velocity. Chronic lead intoxication in children. *Am J Dis Child*, 125(1):39-41, 1973. PMID: 4683960.
21. Galaburda M, Rosman NP, Haddow JE: Thyroid storm in an 11-year-old boy managed by propranolol. *Pediatrics*, 53(6):920-922, 1974. PMID: 4832434.
22. Lee KD, Lovejoy FH Jr, Haddow JE: Childhood methadone intoxication. *Clin Pediatr (Phila)*, 13(1):66-68, 1974. PMID: 4809614.
23. Haddow JE, Cohen DL: Understanding and managing hypernatremic dehydration. *Pediatr Clin North Am*, 21(2):435-441, 1974. PMID: 4837172.
24. Kushlan MC, Haddow JE, Lester R: In vitro enhancement of erythrocyte mercury uptake by spironolactone. *Toxicol Appl Pharmacol*, 31(3):527-533, 1975. PMID: 1145636.
25. Haddow JE, Gall DG: The hairless, odorless axilla: an example of selective end-organ unresponsiveness to androgen. *J Maine Med Assoc*, 66(1):11,25, 1975. PMID: 1110314.
26. Haddow JE: An approach to hypocalcemic disorders in children. *J Maine Med Assoc*, 66(1):1-4, 1975. PMID: 234142.
27. Bratton L, Haddow JE: Ingestion of charcoal lighter fluid. *J Pediatr*, 87(4):633-636, 1975. PMID: 1159594.
28. Haddow JE, Ritchie RF: The relevance of alpha-fetoprotein measurements in prenatal diagnosis. *J Maine Med Assoc*, 66(1):12-13, 1975. PMID: 45930.
29. Brem AS, Haddow JE: Hypothyroidism in infancy. *J Maine Med Assoc*, 67(1):1-3, 1976. PMID: 1244411.
30. Haddow JE, Lester R: Biliary copper excretion in the rat is enhanced by spironolactone. *Drug Metab Dispos*, 4(5):499-503, 1976. PMID: 10150.
31. Robotham JL, Haddow JE: Rhabdomyolysis and myoglobinuria in childhood. *Pediatr Clin North Am*, 23(2):279-301, 1976. PMID: 1272621.
32. Haddow JE: Pregnancy-related alpha-fetoprotein testing. Guidelines in usage and interpretation. *J Maine Med Assoc*, 67(1):6-8, 1976. PMID: 53255.
33. Chute A, Haddow JE, Ritchie RF: Improved electroimmunoassay of factor VIII-related antigen. *Clin Chem*, 23(3):602-603, 1977. PMID: 837551.

34. Haddow JE, Herskowitz J, Mauer E, Morris M: Hypoparathyroidism resulting from biologically ineffective parathormone in a phenotypically normal child. *J Maine Med Assoc*, 69(1):9-12, 1978. PMID: 618998.
35. Haddow JE, Cowchock FS, Macri JN, Munson M, Baldwin P, Aldrich N: Second trimester amniotic fluid protein values from normal, neural tube defect, and fetal demise pregnancies after exclusion of maternal blood contamination by testing for pregnancy-associated macroglobulin. *Pediatr Res*, 12(3):243-248, 1978. PMID: 643395.
36. Rosman NP, Shapiro MB, Haddow JE: Muscle weakness caused by an iodine-deficient diet: investigation of a nutritional myopathy. *J Neuropathol Exp Neurol*, 37(2):192-211, 1978. PMID: 632848.
37. Haddow JE, Robotham JL: Acute interstitial nephritis in children - a process produced by streptococcal infection and by chemotherapeutic agents. A review. *J Maine Med Assoc*, 69(1):1-6, 1978. PMID: 618994.
38. Haddow JE, Kloza EM: Alpha-fetoprotein screening on a U.S. regional basis. *Nature*, 280(5722):444, 1979. PMID: 88677.
39. Bromberger PI, Haddow JE: Hypernatremic dehydration in infancy as a presenting sign of underlying disease. *J Maine Med Assoc*, 70(1):28-29, 1979. PMID: 422902.
40. Thompson DK, Haddow JE: Serial monitoring of serum alpha-fetoprotein and chorionic gonadotropin in males with germ cell tumors. *Cancer*, 43(5):1820-1829, 1979. PMID: 87255.
41. Haddow JE, Macri JN: Prenatal screening for neural tube defects. *JAMA*, 242(6):515-516, 1979. PMID: 376891.
42. Haddow JE, Macri JN, Munson M: The amnion regulates movement of fetally derived alpha-fetoprotein into maternal blood. *J Lab Clin Med*, 94(2):344-347, 1979. PMID: 88493.
43. Macri JN, Haddow JE, Weiss RR: Screening for neural tube defects in the United States: A Summary of the Scarborough Conference. *Am J Obstet Gynecol*, 133(2):119-125, 1979. PMID: 84533.
44. Kloza EM, Haddow JE: Maternal serum alpha-fetoprotein screening. *Am J Obstet Gynecol*, 136(1):145, 1980. PMID: 6153250.
45. Wald NJ, Cuckle HS, Haddow JE: Should ultrasound be used to estimate gestational age in the screening and antenatal diagnosis of open neural tube defects? *Lancet*, 2(8196):690, 1980. PMID: 6106799.
46. Holman M, Knight G, Haddow J: Acetylthiocholine iodide for detecting acetylcholinesterase activity in amniotic fluid. *Lancet*, 2(8195 pt 1):651, 1980. PMID: 6107446.
47. Haddow JE, Thompson DK, Kloza EM: Maternal hepatoma detected during serum AFP screening. *Lancet*, 2(8198):806-807, 1980. PMID: 615909.
48. Bromberger P, Chandler B, Gezon H, Haddow JE: Rapid detection of neonatal group B streptococcal infections by latex agglutination. *J Pediatr*, 96:104-106, 1980. PMID: 6985656.
49. Haddow JE, Kloza EM, Knight GJ, Smith DE: Relation between maternal weight and serum alpha-fetoprotein concentration during the second trimester. *Clin Chem*, 27(1):133-134, 1981. PMID: 6160923.
50. Haddow JE, Morin ME, Holman MS, Miller WA: Acetylcholinesterase and fetal malformations: modified qualitative technique for diagnosis of neural tube defects. *Clin Chem*, 27(1):61-63, 1981. PMID: 6160926.
51. Thompson DK, Haddow JE, Smith DE, Ritchie RF: Serum protein changes in women with early breast cancer. *Cancer*, 48(3):793-798, 1981. PMID: 7248907.
52. Knight GJ, Kloza EM, Smith DE, Haddow JE: Efficiency of human placental lactogen and alpha-fetoprotein measurement in twin pregnancy detection. *Am J Obstet Gynecol*, 141(5):585-586, 1981. PMID: 6170227.
53. Hudson GA, Ritchie RF, Haddow JE: Method for testing antiserum titer and avidity in nephelometric systems. *Clin Chem*, 27(11):1838-1844, 1981. PMID: 6975190.
54. Kaplan MM, Larsen PR, Crantz FR, Dzau VJ, Rossing TH, Haddow JE: Prevalence of abnormal thyroid function test results in patients with acute medical illnesses. *Am J Med*, 72(1):9-16, 1982. PMID: 6800256.
55. Knight GJ, Pulkkinen AJ, Haddow JE: Levels of C-peptide in second trimester amniotic fluid. *Am J Obstet Gynecol*, 142(8):1062-1063, 1982. PMID: 7072778.

56. Moses AC, Lawlor J, Haddow JE, Jackson IM: Familial euthyroid hyperthyroxinemia resulting from increased thyroxine binding to thyroxine-binding prealbumin. *N Engl J Med*, 306(16):966-969, 1982. PMID: 6801514.
57. Haddow JE, Knight GJ, Kloza EM: Alpha-fetoprotein screening in pregnancy - a test whose time has come. *Ariz Med*, 39(7):436-439, 1982. PMID: 6181763.
58. Haddow JE, Miller WA: Prenatal diagnosis of open neural tube defects. *Methods Cell Biol*, 26:67-94, 1982. PMID: 6182446.
59. Brock DJH, Barlow RD, Wald NJ, Smith AD, Haddow JE, Goldfine C, Holman M: Fetal calf serum as a cause of false positive amniotic fluid acetylcholinesterase gel tests. *Lancet*, 2(8306):1044, 1982. PMID: 6127524.
60. Haddow JE: Screening for spinal defects. *Hosp Pract (Off Ed)*, 17(1):128-138, 1982. PMID: 6185408.
61. Goldfine C, Haddow JE, Hudson GA, Miller WA: Densitometry as an aid in amniotic fluid gel acetylcholinesterase analysis. *Am J Obstet Gynecol*, 145(3):317-318, 1983. PMID: 6186143.
62. Goldfine C, Miller WA, Haddow JE: Amniotic fluid gel cholinesterase density ratios in fetal open defects of the neural tube and ventral wall. *Br J Obstet Gynaecol*, 90(3):238-240, 1983. PMID: 6338901.
63. Thompson DK, Haddow JE, Smith DE, Ritchie RF: Elevated serum acute phase protein levels as predictors of disseminated breast cancer. *Cancer*, 51(11):2100-2104, 1983. PMID: 6188525.
64. Hudson GA, Haddow JE, Ritchie RF: Disparity in antiserum avidity as measured by nephelometry, radial immunodiffusion, and column-binding strength. *Clin Chim Acta*, 130(2):239-244, 1983. PMID: 6409453.
65. Fisher NC, Hinds-Aldrich N, Haddow JE, Hudson GA: A cellulose sandwich fluoroimmunoassay for Factor VIII-related antigen. *Thromb Res*, 31(1):145-154, 1983. PMID: 6412396.
66. Hostetter MK, Levy HL, Winter HS, Knight GJ, Haddow JE: Evidence for liver disease preceding amino acid abnormalities in hereditary tyrosinemia. *N Engl J Med*, 308(21):1265-1267, 1983. PMID: 6188953.
67. Carpenter MW, Curci MR, Dibbins AW, Haddow JE: Perinatal management of ventral wall defects. *Obstet Gynecol*, 64(5):646-651, 1984. PMID: 6238249.
68. Wald NJ, Barlow RD, Cuckle HS, Turnbull AC, Goldfine C, Haddow JE: Ratio of amniotic fluid acetylcholinesterase to pseudocholinesterase as an antenatal diagnostic test for exomphalos and gastroschisis. *Br J Obstet Gynaecol*, 91(9):882-884, 1984. PMID: 636841.
69. Haddow JE, Knight GJ, Palomaki G: Does smoking influence serum alpha-fetoprotein levels in mid-trimester pregnancies? *Br J Obstet Gynaecol*, 91(12):1188-1191, 1984. PMID: 6083799.
70. Wald NJ, Boreham J, Bailey A, Ritchie C, Haddow JE, Knight GJ: Urinary cotinine as marker of breathing other people's tobacco smoke. *Lancet*, 1(8370):230-231, 1984. PMID: 6141373.
71. Haddow JE, Milunsky A: Deregulation of screening for alpha-fetoprotein in pregnancy. *N Engl J Med*, 310(25):1669-1670, 1984. PMID: 6203037.
72. Haddow JE, Knight GJ, Pulkkinen AJ, Smith DE: The relationship between serum beta 1-glycoprotein and alpha-fetoprotein levels in the second trimester and birth weight. *Am J Obstet Gynecol*, 148(1):108-109, 1984. PMID: 6197882.
73. Knight GJ, Wylie P, Holman MS, Haddow JE: Improved ¹²⁵I radioimmunoassay for cotinine by selective removal of bridge antibodies. *Clin Chem*, 31(1):118-121, 1985. PMID: 3880672.
74. Haddow JE: Identifying fetal disorders by maternal serum alpha-fetoprotein screening. *Practitioner*, 229(1406):721-725, 1985. PMID: 2412219.
75. Is there a future for lower-tar-yield cigarettes? Participants of the Fourth Scarborough Conference on Preventive Medicine. *Lancet*, 2(8464):1111-1114, 1985. PMID: 2865577.
76. Palomaki GE, Knight GJ, Kloza EM, Haddow JE: Maternal weight adjustment and low serum alpha-fetoprotein values. *Lancet*, 1(8426):468, 1985. PMID: 2579300.
77. Milunsky A, Haddow JE: Cautions about maternal serum alpha-fetoprotein screening. *N Engl J Med*, 313(11):694, 1985. PMID: 2410789.
78. Knight GJ, Palomaki GE, Haddow JE: Maternal serum alpha-fetoprotein: a problem with a test kit. *N Engl J Med*, 314(8):516, 1986. PMID: 2418356.
79. Haddow JE, Hill LE, Kloza EM, Thanhauser D: Neural tube defects after gastric bypass. *Lancet*, 1(8493):1330, 1986. PMID: 2872457.

80. Haddow JE, Palomaki GE, Wald NJ, Cuckle HS: Maternal serum alpha-fetoprotein screening for Down syndrome and repeat testing. *Lancet*, 2(8521-22):1460, 1986. PMID: 2431241.
81. Haddow JE, Palomaki GE, Knight GJ: Use of serum cotinine to assess the accuracy of self reported non-smoking. *Br Med J (Clin Res Ed)*, 293(6557):1306, 1986. PMID: 3096477.
82. Haddow JE, Knight GJ, Kloza EM, Palomaki GE: Alpha-fetoprotein, vaginal bleeding, and pregnancy risk. *Br J Obstet Gynaecol*, 93(6):589-593, 1986. PMID: 2425844.
83. Haddow JE, Knight GJ, Palomaki GE, Kloza EM, Wald NJ: Cigarette consumption and serum cotinine in relation to birthweight. *Br J Obstet Gynaecol*, 94(7):678-681, 1987. PMID: 3620415.
84. Biber A, Scherer G, Hoepfner I, Adlkofer F, Heller WD, Haddow JE, Knight GJ: Determination of nicotine and cotinine in human serum and urine: an interlaboratory study. *Toxicol Lett*, 35(1):45-52, 1987. PMID: 3810681.
85. Palomaki GE, Haddow JE: Maternal serum alpha-fetoprotein, age, and Down syndrome risk. *Am J Obstet Gynecol*, 156(2):460-463, 1987. PMID: 2435155.
86. Haddow JE, Palomaki GE, Knight GJ: Can low birth weight after elevated maternal serum alpha-fetoprotein be explained by maternal weight? *Obstet Gynecol*, 70(1):26-28, 1987. PMID: 2439965.
87. Haddow JE, Hill LE, Palomaki GE, Knight GJ: Very low versus undetectable maternal serum alpha-fetoprotein values and fetal death. *Prenat Diagn*, 7(6):401-406, 1987. PMID: 2443907.
88. Page LA, Haddow JE: Self-limited neonatal hyperparathyroidism in familial hypocalciuric hypercalcemia. *J Pediatr*, 111(2):261-264, 1987. PMID: 3612401.
89. Knight GJ, Haddow JA, Palomaki GE, Haddow JE: Selection and validation of alpha-fetoprotein assay kits for the screening of Down syndrome. *Am J Obstet Gynecol*, 156(6):1557-1559, 1987. PMID: 2438936.
90. Palomaki GE, Haddow JE: Combining maternal age and serum alpha-fetoprotein in predicting the risk of Down syndrome. *Obstet Gynecol*, 69(4):683, 1987. PMID: 2434896.
91. Kloza EM, Hill LE, Haddow JE: Open fetal malformations in incorrectly dated pregnancies with initially low maternal serum alpha-fetoprotein results. *Lancet*, 2(8553):275-276, 1987. PMID: 2441216.
92. Haddow JE, Knight GJ, Palomaki GE, Haddow PK: Estimating fetal morbidity and mortality resulting from cigarette smoke exposure by measuring cotinine levels in maternal serum. *Prog Clin Biol Res*, 281:289-300, 1988. PMID: 3174713.
93. Haddow JE: Screening for fetal disorders by measuring alpha-fetoprotein levels in maternal serum. *Ala J Med Sci*, 25(2):168-172, 1988. PMID: 2455453.
94. Canick JA, Knight GJ, Palomaki GE, Haddow JE, Cuckle HS, Wald NJ: Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome. *Br J Obstet Gynaecol*, 95(4):330-333, 1988. PMID: 2968116.
95. Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Canick JA, Haddow JE, Knight GJ, Palomaki GE: Maternal serum unconjugated oestriol as an antenatal screening test for Down's syndrome. *Br J Obstet Gynaecol*, 95(4):334-341, 1988. PMID: 2454652.
96. Palomaki GE, Hill LE, Knight GJ, Haddow JE, Carpenter M: Second-trimester maternal serum alpha-fetoprotein levels in pregnancies associated with gastroschisis and omphalocele. *Obstet Gynecol*, 71(6 Pt 1):906-909, 1988. PMID: 2453005.
97. Haddow JE, Knight GJ, Palomaki GE, McCarthy JE: Second-trimester serum cotinine levels in nonsmokers in relation to birth weight. *Am J Obstet Gynecol*, 159(2):481-484, 1988. PMID: 3407708.
98. Wald NJ, Cuckle HS, Densem J, Nanchahal K, Royston P, Chard T, Haddow JE, Knight GJ, Palomaki GE, Canick J: Maternal serum screening for Down's syndrome in early pregnancy. *BMJ*, 297(6653):883-887, 1988. PMID: 2460174.
99. Cuckle HS, Wald NJ, Stone R, Densem J, Haddow JE, Knight GJ: Maternal serum thyroid antibodies in early pregnancy and fetal Down's syndrome. *Prenat Diagn*, 8(6):439, 1988. PMID: 2974954.
100. Martin L, Chavez GF, Adams MJ, Mason EE, Hanson JW, Haddow JE, Currier RW: Gastric bypass surgery as maternal risk factor for neural tube defects. *Lancet*, 1(8586):640-641, 1988. PMID: 2894563.

101. Greene MF, Haddow JE, Palomaki GE, Knight GJ: Maternal serum alpha-fetoprotein levels in diabetic pregnancies. *Lancet*, 2(8606):345-346, 1988. PMID: 2456437.
102. Cuckle HS, Wald NJ, Barkai G, Fuhrmann W, Altland K, Brambati B, Knight GJ, Palomaki GE, Haddow JE, Canick JA: First-trimester biochemical screening for Down syndrome. *Lancet*, 2(8615):851-852, 1988. PMID: 2902296.
103. Goldfine C, Knight GJ, Haddow JE, Palomaki GE: Amniotic fluid acetylcholinesterase measurements: comparing immunochemical and polyacrylamide gel techniques. *Prenat Diagn*, 9(3):167-172, 1989. PMID: 2710743.
104. Palomaki GE, Williams J, Haddow JE: Combining maternal serum alpha-fetoprotein measurements and age to screen for Down syndrome in pregnant women under age 35. An eight center prospective collaborative study. *Am J Obstet Gynecol*, 160(3):575-581, 1989. PMID: 2467563.
105. Craig WY, Palomaki GE, Haddow JE: Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. *BMJ*, 298(6676):784-788, 1989. PMID: 2496857.
106. Knight GJ, Palomaki GE, Lea DH, Haddow JE: Exposure to environmental tobacco smoke measured by cotinine ¹²⁵I radioimmunoassay. *Clin Chem*, 35(6):1036-1039, 1989. PMID: 2731343.
107. Goldfine C, Haddow JE, Knight GJ, Palomaki GE: Amniotic fluid alpha-fetoprotein and acetylcholinesterase measurements in pregnancies associated with gastroschisis. *Prenat Diagn*, 9(10):697-700, 1989. PMID: 2480589.
108. Wald NJ, Cuckle HS, Sneddon J, Haddow JE, Palomaki GE: Screening for Down syndrome. *Am J Hum Genet*, 44(4):586-590, 1989. PMID: 2467558.
109. Osathanondh R, Canick JA, Abell KB, Stevens LD, Palomaki GE, Knight GJ, Haddow JE: Second trimester screening for trisomy 21. *Lancet*, 2(8653):52, 1989. PMID: 2567830.
110. Craig WY, Palomaki GE, Johnson AM, Haddow JE: Cigarette smoking-associated changes in blood lipid and lipoprotein levels in the 8- to 19-year-old age group: a meta-analysis. *Pediatrics*, 85:155-158, 1990. PMID: 2136949.
111. Cuckle HS, Wald NJ, Densem JW, Royston P, Knight GJ, Haddow JE, Palomaki GE, Canick JA: The effect of smoking in pregnancy on maternal serum alpha-fetoprotein, unconjugated oestriol, human chorionic gonadotrophin, progesterone and dehydroepiandrosterone sulphate levels. *Br J Obstet Gynaecol*, 97(3):272-274, 1990. PMID: 1692234.
112. Palomaki GE, Knight GJ, Holman MS, Haddow JE: Maternal serum alpha-fetoprotein screening for fetal Down syndrome in the United States: results of a survey. *Am J Obstet Gynecol*, 162(2):317-321, 1990. PMID: 1689959.
113. Johnson AM, Palomaki GE, Haddow JE: Maternal serum alpha-fetoprotein levels in pregnancies among black and white women with fetal open spina bifida: a United States collaborative study. *Am J Obstet Gynecol*, 162(2):328-331, 1990. PMID: 1689960.
114. Johnson AM, Palomaki GE, Haddow JE: The effect of adjusting maternal serum alpha-fetoprotein levels for maternal weight in pregnancies with fetal open spina bifida. A United States collaborative study. *Am J Obstet Gynecol*, 163(1 Pt 1):9-11, 1990. PMID: 1695816
115. Chilmonczyk BA, Knight GJ, Palomaki GE, Pulkkinen AJ, Williams J, Haddow JE: Environmental tobacco smoke exposure during infancy. *Am J Public Health*, 80(10):1205-1208, 1990. PMID: 2400031.
116. Canick JA, Knight GJ, Palomaki GE, Haddow JE: Second-trimester levels of maternal serum unconjugated estriol and human chorionic gonadotropin in pregnancies affected by fetal anencephaly and open spina bifida. *Prenat Diagn*, 10(11):733-737, 1990. PMID: 22284275.
117. Moses AC, Rosen HN, Moller DE, Tsuzaki S, Haddow JE, Lawlor J, Liepniesk JJ, Nichols WC, Benson MD: A point mutation in transthyretin increases affinity for thyroxine and produces euthyroid hyperthyroxinemia. *J Clin Invest*, 86(6):2025-2033, 1990. PMID: 1979335.
118. Haddow JE: Prenatal screening for open neural tube defects, Down's syndrome, and other major fetal disorders. *Semin Perinatol*, 14(6):488-503, 1990. PMID: 1706536.
119. Haddow JE, Palomaki GE, Knight GJ, Canick JA, Wald NJ, Cuckle HS: Maternal serum unconjugated estriol levels are lower in the presence of fetal Down syndrome. *Am J Obstet Gynecol*, 163(4 Pt 1):1372-1374, 1990. PMID: 1699418.
120. Klein RZ, Haddow JE, Faix JD, Brown RS, Hermos RJ, Pulkkinen A, Mitchell ML: Prevalence of thyroid deficiency in pregnant women. *Clin Endocrinol (Oxf)*, 35(1):41-46, 1991. PMID: 1889138.

121. Haddow JE, Knight GJ, Kloza EM, Palomaki GE, Wald NJ: Cotinine-assisted intervention in pregnancy to reduce smoking and low birthweight delivery. *Br J Obstet Gynaecol*, 98(9):859-865, 1991. PMID: 1716979.
122. Haddow JE, Rote NS, Dostal-Johnson D, Palomaki GE, Pulkkinen AJ, Knight GJ: Lack of an association between late fetal death and antiphospholipid antibody measurements in the second trimester. *Am J Obstet Gynecol*, 165(5 Pt 1):1308-1312, 1991. PMID: 1957852.
123. Rose NC, Haddow JE, Palomaki GE, Knight GJ: Self-rated physical activity level during the second trimester and pregnancy outcome. *Obstet Gynecol*, 78(6):1078-1080, 1991. PMID: 1945211.
124. Wald NJ, Cuckle HS, Haddow JE, Doherty RA, Knight GJ, Palomaki GE: Sensitivity of ultrasound in detecting spina bifida. *N Engl J Med*, 324(11):769-770, 1991. PMID: 1705312.
125. Haddow JE, Knight GJ, Palomaki GE, Johnson AM: Maternal serum alpha-fetoprotein in congenital hypothyroidism. *Lancet*, 337(8746):922, 1991. PMID: 1707473.
126. Wald NJ, Densem JW, Haddow JE, Palomaki GE, Knight GJ, Canick JA: Prenatal screening for Down's syndrome. *BMJ*, 303(6804):715, 1991. PMID: 1833015.
127. Haddow JE, Holman MS, Palomaki GE: Can gestational dates routinely derived from very early ultrasound be used to interpret maternal serum alpha-fetoprotein measurements? *Prenat Diagn*, 12(1):65-68, 1992. PMID: 1372973.
128. Chilmonczyk BA, Palomaki GE, Knight GJ, Williams J, Haddow JE: An unsuccessful cotinine-assisted intervention strategy to reduce environmental tobacco smoke exposure during infancy. *Am J Dis Child*, 146(3):357-360, 1992. PMID: 1543187.
129. Greenberg F, Faucett A, Rose E, Bancalari L, Kardon NB, Mizejewski G, Haddow JE, Alpert E: Congenital deficiency of alpha-fetoprotein. *Am J Obstet Gynecol*, 167(2):509-511, 1992. PMID: 1379776.
130. Haddow JE, Palomaki GE, Knight GJ, Williams J, Pulkkinen A, Canick JA, Saller DN, Bowers GB: Prenatal screening for Down's syndrome with use of maternal serum markers. *N Engl J Med*, 327(9):588-593, 1992. PMID: 1379344.
131. Pueschel SM, Craig WY, Haddow JE: Lipids and lipoproteins in persons with Down's syndrome. *J Intellect Disabil Res*, 36(Pt 4):365-369, 1992. PMID: 1388078.
132. Palomaki GE, Knight GJ, Haddow JE, Canick JA, Saller DN, Panizza DS: Prospective intervention trial of a screening protocol to identify fetal trisomy 18 using maternal serum alpha-fetoprotein, unconjugated aetrial and human chorionic gonadotropin. *Prenat Diagn*, 12(11):925-930, 1992. PMID: 1283634.
133. Donnenfeld AE, Pulkkinen A, Palomaki GE, Knight GJ, Haddow JE: Simultaneous fetal and maternal cotinine levels in pregnant women smokers. *Am J Obstet Gynecol*, 168(3 Pt 1):781-782, 1993. PMID: 8456879.
134. Palomaki GE, Knight GJ, Haddow JE, Canick JA, Wald NJ, Kennard A: Cigarette smoking and levels of maternal serum alpha-fetoprotein, unconjugated estriol, and hCG: Impact on Down syndrome screening. *Obstet Gynecol*, 81(5 Pt 1):675-678, 1993. PMID: 7682315.
135. Haddow JE, Palomaki GE, Holman MS: Young maternal age and smoking during pregnancy as risk factors for gastroschisis. *Teratology*, 47(3):225-228, 1993. PMID: 8475465.
136. Chilmonczyk BA, Salmun LM, Megathlin KN, Neveux LM, Palomaki GE, Knight GJ, Pulkkinen AJ, Haddow JE: Association between exposure to environmental tobacco smoke and exacerbations of asthma in children. *N Engl J Med*, 328(23):1665-1669, 1993. PMID: 8487825.
137. Palomaki GE, Knight GJ, McCarthy J, Haddow JE, Eckfeldt JH: Maternal serum screening for fetal Down syndrome in the United States: A 1992 survey. *Am J Obstet Gynecol*, 169(6):1558-1562, 1993. PMID: 7705530.
138. Palomaki GE, Haddow JE: Is it time for population-based prenatal screening for fragile-X? *Lancet*, 341(8841):373-374, 1993. PMID: 8094139.
139. Knight GJ, Palomaki GE, Haddow JE, Miller WA, Bersinger NA, Schneider H: Pregnancy associated plasma protein A as a marker for Down syndrome in the second trimester of pregnancy. *Prenat Diagn*, 13(3):222-223, 1993. PMID: 8506222.
140. Palomaki GE, Knight GJ, Haddow JE: Is MoM bashing justified? *Am J Hum Genet*, 53(3):777-781, 1993. PMID: 7688935.
141. Palomaki GE, Knight GJ, Haddow JE: Calculating amniotic fluid alpha-fetoprotein median values in the first trimester. *Prenat Diagn*, 13(9):887-889, 1993. PMID: 7506409.

142. Haddow JE, Knight GJ, Palomaki GE: Antenatal screening for Down's syndrome. Performance of difference markers remains confused. *BMJ*, 307(6905):679-680, 1993. PMID: 8401065.
143. Wald NJ, Hackshaw A, Haddow JE, Palomaki GE, Knight GJ: Use of free beta-hCG in Down's syndrome screening. *Ann Clin Biochem*, 30(Pt 5):512-518, 1993. PMID: 7504428.
144. Wald NJ, Law M, Watt H, Wu T, Bailey A, Johnson AM, Craig WY, Ledue TB, Haddow JE: Apolipoproteins and ischaemic heart disease: implications for screening. *Lancet*, 343(8889):75-79, 1994. PMID: 7903777.
145. Haddow JE, Ledue TB: Preventing manifestations of hereditary haemochromatosis through population based screening. *J Med Screen*, 1(1):16-21, 1994. PMID: 8790482.
146. Haddow JE, Knight GJ, Palomaki GE, Neveux LM, Chilmonczyk BA: Replacing creatinine measurements with specific gravity values to adjust urine cotinine concentrations. *Clin Chem*, 40(4):562-564, 1994. PMID: 8149610.
147. Rose NC, Palomaki GE, Haddow JE, Goodman DB, Mennuti MT: Maternal serum alpha-fetoprotein screening for chromosomal abnormalities: a prospective study in women aged 35 and older. *Am J Obstet Gynecol*, 170(4):1073-1078, 1994. PMID: 7513121.
148. Haddow JE, Palomaki GE, Knight GJ, Cunningham CG, Lustig LS, Boyd PA: Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening. *N Engl J Med*, 330(16):1114-1118, 1994. PMID: 7510852.
149. Palomaki GE, Knight GJ, Haddow JE: Human chorionic gonadotropin and unconjugated estriol measurements in insulin-dependent diabetic pregnant women being screened for fetal Down syndrome. *Prenat Diagn*, 14(1):65-68, 1994. PMID: 7514290.
150. Saller DN, Canick JA, Palomaki GE, Knight GJ, Haddow JE: Second-trimester maternal serum alpha-fetoprotein, unconjugated estriol and hCG levels in pregnancies with ventral wall defects. *Obstet Gynecol*, 84(5):852-855, 1994. PMID: 7524003.
151. Palomaki GE, Bradley LA, Haddow JE: A new approach to analysing fluorescence in situ hybridization data for rapid detection of aneuploidy in amniocytes. *J Med Screen*, 1(2):96-97, 1994. PMID: 8790494.
152. Haddow JE, Knight GJ, Palomaki GE: Prenatal ultrasound screening and perinatal outcome. *N Engl J Med*, 330(8):571, 1994. PMID: 8302328.
153. Doherty RA, Palomaki GE, Kloza EM, Erickson JL, Dostal DA, Haddow JE: Prenatal screening for cystic fibrosis. *Lancet*, 343(8890):172, 1994. PMID: 7904015.
154. Ledue TB, Craig WJ, Ritchie RF, Haddow JE: Influence of blood donation and iron supplementation on indicators of iron status. *Clin Chem*, 40(7 Pt 1):1345-1346, 1994. PMID: 8013112.
155. Haddow JE, Palomaki GE: Multiparity and Down's syndrome. *Lancet*, 344(8927):956, 1994. PMID: 7934367.
156. Palomaki GE, Haddow JE: Comparison of two Down syndrome screening strategies for women aged 35 and older. *Prenat Diagn*, 14(9):898-899, 1994. PMID: 7531329.
157. Haddow JE, Knight GJ, Palomaki GE: Prenatal ultrasound screening and perinatal outcome. *N Engl J Med*, 330(8):571, 1994. PMID: 832328.
158. Palomaki GE, Williams J, Haddow JE, Natowicz MR: Tay-Sachs disease in persons of French-Canadian heritage in northern New England. *Am J Med Genet*, 56(4):409-412, 1995. PMID: 7604851.
159. Haddow JE, Palomaki GE, Knight GJ: Effect of parity on human chorionic gonadotrophin levels and Down's syndrome screening. *J Med Screen*, 2(1):28-30, 1995. PMID: 7497141.
160. Palomaki GE, Haddow JE, Knight GJ, Wald NJ, Kennard A, Canick JA, Saller DN, Blitzer MG, Dickerman LH, Fisher R, Hansmann D, Hansmann M, Luthy DA, Summers AM, Wyatt P: Risk-based prenatal screening for trisomy 18 using alpha-fetoprotein, unconjugated oestriol and human chorionic gonadotropin. *Prenat Diagn*, 15(8):713-723, 1995. PMID: 7479589.
161. Simpson JL, Palomaki GE, Mercer B, Haddow JE, Andersen R, Sibai B, Elias S: Associations between adverse perinatal outcome and serially obtained second- and third-trimester maternal serum alpha-fetoprotein measurements. *Am J Obstet Gynecol*, 173(6):1742-1748, 1995. PMID: 8610755.
162. Adams MJ, Khoury MJ, Scanlon KS, Stevenson RE, Knight GJ, Haddow JE, Sylvester GC, Cheek JE, Henry J, Stabler SP, Allen RH: Elevated midtrimester serum methylmalonic acid levels as a risk factor for neural tube defects. *Teratology*, 51(5):311-317, 1995. PMID: 7482352.

163. Haddow JE, Palomaki GE: Is maternal obesity a risk factor for open neural tube defects? *Am J Obstet Gynecol*, 172(1 Pt 1):245-247, 1995. PMID: 7847555.
164. Haddow JE, Palomaki GE: Use of personal records for research purposes. Restrictions unnecessary and obstructive. *BMJ*, 310(6974):258, 1995. PMID: 7866149.
165. Miller WA, Haddow JE: When is it appropriate to apply fetal cell isolation clinically? *Am J Obstet Gynecol*, 172(3):1064-1065, 1995. PMID: 7892856.
166. Wald NJ, Brock DJH, Haddow JE, Doherty RA: Antenatal screening for cystic fibrosis. *BMJ*, 310(6988):1199, 1995. PMID: 7767177.
167. Craig WY, Kloza EM, Haddow JE, Hitchcock JL, Eldrup-Jorgensen J: Lipoprotein(a) levels in peripheral atherosclerotic disease. *J Vasc Surg*, 21(3):541-542, 1995. PMID: 7877242.
168. Haddow JE, Palomaki GE, Sepulveda D: Smoking cessation counseling during routine public prenatal care. *Am J Public Health*, 85(10):1451-1452, 1995. PMID: 7573639.
169. Wald NJ, Kennard A, Watt H, Haddow JE, Palomaki GE, Knight GJ, Canick JA: Decision analysis and screening for Down's syndrome. Testing should be in all women. *BMJ*, 311(7016):1372, 1995. PMID: 7496310.
170. Palomaki GE, Neveux LM, Haddow JE: Are DADs (discriminant aneuploidy detection) as good as MoMs (multiples of the median)? *Am J Obstet Gynecol*, 173(5):1895-1897, 1995. PMID: 7503224.
171. Neveux LM, Palomaki GE, Knight GJ, Haddow JE: Multiple marker screening for Down syndrome in twin pregnancies. *Prenat Diagn*, 16(1):29-34, 1996. PMID: 8221849.
172. Palomaki GE, Neveux LM, Haddow JE: Can reliable Down's syndrome detection rates be determined from prenatal screening intervention trials? *J Med Screen*, 3(1):12-17, 1996. PMID: 8861045.
173. Doherty RA, Palomaki GE, Kloza EM, Erickson JL, Haddow JE: Couple-based prenatal cystic fibrosis screening in primary care settings. *Prenat Diagn*, 16(5):397-404, 1996. PMID: 8843996.
174. Neveux LM, Palomaki GE, Larrivee DA, Knight GJ, Haddow JE: Refinements in managing maternal weight adjustment for interpreting prenatal screening results. *Prenat Diagn*, 16(12):1115-1119, 1996. PMID: 8994247.
175. Bradley LA, Haddow JE, Palomaki GE: Population screening for haemochromatosis: Expectations based on studying relatives of symptomatic probands. *J Med Screen*, 3(4):171-177, 1996. PMID: 9041480.
176. Bradley LA, Haddow JE, Palomaki GE: Population screening for haemochromatosis: A unifying analysis of published intervention trials. *J Med Screen*, 3(4):178-184, 1996. PMID: 9041481.
177. Doherty RA, Bradley LA, Haddow JE: Prenatal screening for cystic fibrosis: an updated perspective. *Am J Obstet Gynecol*, 176(2):268-270, 1997. PMID: 9065166.
178. Doherty RA, Bradley LA, Haddow JE: Cost effectiveness of antenatal screening for cystic fibrosis. Couple screening would be easier for many centres. *BMJ*, 312(7035):909, 1996. PMID: 8611896.
179. Palomaki GE, Haddow JE, Beauregard LJ: Prenatal screening for Down's syndrome in Maine, 1980 to 1993. *N Engl J Med*, 334(21):1409-1410, 1996. PMID: 8614443.
180. Knight GJ, Haddow JE, Palomaki GE, Donhowe JM, Witte DL: Computer software programs and Down's syndrome risk calculations. *Lancet*, 347(9014):1553, 1996. PMID: 8684123.
181. Haddow JE, Palomaki GE, Knight GJ, Williams J, Chilmonczyk BA: Intervening to reduce environmental tobacco smoke exposure in infants. *Pediatrics*, 98(3 Pt 1):513, 1996. PMID: 8784385.
182. Palomaki GE, Haddow JE: Gestational dating and Down's syndrome screening. *Ann Clin Biochem*, 33(Pt 4):359-361, 1996. PMID: 8836400.
183. Palomaki GE, Haddow JE: Nicked free β -subunit and Down syndrome screening. *Am J Obstet Gynecol*, 175(4 Pt 1):1075, 1996. PMID: 8885779.
184. Haddow JE, Palomaki GE: Similarities in women's decision-making in the U.S. and U.K. during prenatal screening for Down's syndrome. *Prenat Diagn*, 16(12):1161-1162, 1996. PMID: 8994255.
185. Hackshaw AK, Wald NJ, Haddow JE: Down's syndrome screening with nuchal translucency. *Lancet*, 348(9043):1740, 1996. PMID: 8973459.
186. Bradley LA, Canick JA, Palomaki GE, Haddow JE: Undetectable maternal serum unconjugated estriol levels in the second trimester: risk of perinatal complications associated with placental sulfatase deficiency. *Am J Obstet Gynecol*, 176(3):531-535, 1997. PMID: 9077601.

187. Palomaki GE, Knight GJ, McCarthy JE, Haddow JE, Donhowe JM: Maternal serum screening for Down syndrome in the United States: a 1995 survey. *Am J Obstet Gynecol*, 176(5):1046-1051,1997. PMID: 9166166.
188. Haddow JE: Why the term "carrier screening" should be abandoned. *J Med Screen*, 4(1):1, 1997. PMID: 9200052.
189. Haddow JE, Palomaki GE, Knight GJ, Williams J, Miller WA, Johnson A: Screening of maternal serum for fetal Down's syndrome in the first trimester. *N Engl J Med*, 338(14):955-961, 1998. PMID: 9521983.
190. Knight GJ, Palomaki GE, Neveux LM, Fodor KK, Haddow JE: hCG and the free β -subunit as screening tests for Down syndrome. *Prenat Diagn*, 18(3):235-245, 1998. PMID: 9556040.
191. Wald NJ, Watt HC, Haddow JE, Knight GJ: Screening for Down syndrome at 14 weeks of pregnancy. *Prenat Diagn*, 18(3):291-293, 1998. PMID: 9556047.
192. Bradley LA, Johnson DD, Palomaki GE, Haddow JE, Robertson NH, Ferrie RM: Hereditary haemochromatosis mutation frequencies in the general population. *J Med Screen*, 5(1):34-36, 1998. PMID: 9575458.
193. Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE: Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. *Clin Chem*, 44(11):2301-2306, 1998. PMID: 9799757.
194. Haddow JE, Palomaki GE, Knight GJ, Foster DL, Neveux LM: Second trimester screening for Down's syndrome using maternal serum dimeric inhibin-A. *J Med Screen*, 5(3):115-120, 1998. PMID: 9795869.
195. Watt HC, Law MR, Wald NJ, Craig WY, Ledue TB, Haddow JE: Serum triglyceride: a possible risk factor for ruptured abdominal aortic aneurysm. *Int J Epidemiol*, 27(6):949-952, 1998. PMID: 10024187.
196. Haddow JE: Antenatal screening for Down's syndrome: where are we and where next? *Lancet*, 352(9125):336-337, 1998. PMID: 9717914.
197. Haddow JE: Antenatal screening for Down's syndrome. (Author's reply) *Lancet*, 352(9134):1144, 1998. PMID: 9798610.
198. Palomaki GE, Neveux LM, Haddow JE: Current Down syndrome risk estimates are reliable. *Am J Obstet Gynecol*, 178(4):871-872, 1998. PMID: 9579462.
199. Hayde M, Bernaschek G, Stevenson DK, Knight GJ, Haddow JE, Widness JA: Antepartum fetal and maternal carboxyhemoglobin and cotinine levels among cigarette smokers. *Acta Paediatr*, 88(3):327-331, 1999. PMID: 10229047.
200. Palomaki GE, Haddow JE: Age-related prevalence of Down syndrome. *Am J Obstet Gynecol*, 180(6 Pt 1):1597-1598, 1999. PMID: 10368552.
201. Bradley LA, Palomaki GE, Knight GJ, Haddow JE, Opitz JM, Irons M, Kelley RI, Tint GS: Levels of unconjugated estriol and other maternal serum markers in pregnancies with Smith-Lemli-Opitz (RSH) syndrome fetuses. *Am J Med Genet*, 82(4):355-358, 1999. PMID: 10051173.
202. Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, O'Heir CE, Mitchell ML, Hermos RJ, Waisbren SE, Faix JD, Klein RZ: Maternal thyroid deficiency during pregnancy and subsequent psychological development of the child. *N Engl J Med*, 341(8):549-555, 1999. PMID: 10451459.
203. Haddow JE, Bradley LA, Palomaki GE, Doherty RA, Bernhardt BA, Brock DJH, et al: Issues in implementing prenatal screening for cystic fibrosis: Results of a working conference. *Genet Med*, 1(4):129-135, 1999. PMID: 11258347.
204. Haddow JE, Bradley LA, Palomaki GE, Doherty RA. Issues in implementing prenatal screening for cystic fibrosis: Results of a working conference. *J Med Screen*, 6(2):60-66, 1999. PMID: 10444721.
205. Saller DN, Canick JA, Blitzer MG, Palomaki GE, Schwartz S, Blakemore KJ, Haddow JE: Second-trimester maternal serum analyte levels associated with fetal trisomy 13. *Prenat Diagn*, 19(9):813-816, 1999. PMID: 10521837.
206. Haddow JE: Preventing neural tube defects: a major success story with a chapter yet to be written (editorial). *J Med Screen*, 6(4):169, 1999. PMID: 10693059.
207. Haddow JE, Bradley LA: Hereditary haemochromatosis: to screen or not. Conditions for screening are not yet fulfilled. *BMJ*, 319(7209):531-532, 1999. PMID: 10463879.

208. Palomaki GE, Williams JR, Haddow JE: Prenatal screening for open neural-tube defects in Maine. *N Engl J Med*, 340(13):1049-1050, 1999. PMID: 10189295.
209. Haddow JE: Screening for hypothyroidism in adults: supporting data from two population studies. *J Med Screen*, 7(1):1-2, 2000. PMID: 10807137.
210. Allan WC, Haddow JE, Palomaki GE, Williams JR, Mitchell ML, Hermos RJ, Faix JD: Maternal thyroid deficiency and pregnancy complications: implications for population screening. *J Med Screen*, 7(3):127-130, 2000. PMID: 11126160.
211. Haddow JE: In search of better ways to transmit information about screening tests. *J Med Screen*, 7(3):122, 2000. PMID: 11126158.
212. Haddow JE, Palomaki GE, Knight GJ: Response to Hallahan et al. (Letter to the Editor). *Prenat Diagn*, 20(10):790-791, 2000. PMID: 11038454.
213. Mitchell ML, Hermos RJ, Larson CA, Palomaki GE, Haddow JE: Prevalence of GAD autoantibodies in women with gestational diabetes: a retrospective analysis. *Diabetes Care*, 23(11):1705-1706, 2000. PMID: 11092299.
214. Knight GJ, Palomaki GE, Neveux LM, Haddow JE, Lambert-Messerlian GM: Clinical validation of a new dimeric inhibin-A assay suitable for second trimester Down's syndrome screening. *J Med Screen*, 8(1):2-7, 2001. PMID: 11373844.
215. Klein RZ, Sargent JD, Larsen PR, Waisbren SE, Haddow JE, Mitchell ML: Relation of severity of maternal hypothyroidism to cognitive development of offspring. *J Med Screen*, 8(1):18-20, 2001. PMID: 11373843.
216. Allan WC, Timothy K, Vincent GM, Palomaki GE, Neveux LM, Haddow JE: Long QT syndrome in children: the value of rate corrected QT interval and DNA analysis as screening tests in the general population. *J Med Screen*, 8(4):173-177, 2001. PMID: 11743032.
217. Allan WC, Timothy K, Vincent GM, Palomaki GE, Neveux LM, Haddow JE: Long QT syndrome in children: the value of the rate corrected QT interval in children who present with fainting. *J Med Screen*, 8(4):178-182, 2001. PMID: 11743033.
218. Haddow JE: Should we abandon the concept of giving patients "positive" and "negative" screening results? No: we should do better at explaining results. *West J Med*, 174(6):373, 2001. PMID: 11380991.
219. Palomaki GE, Bradley LA, Knight GJ, Craig WY, Haddow JE: Assigning risk for Smith-Lemli-Opitz syndrome as part of 2nd trimester screening. *J Med Screen*, 9(1):43-44, 2002. PMID: 11943798.
220. Palomaki GE, Haddow JE, Bradley LA, FitzSimmons SC: Updated assessment of cystic fibrosis mutation frequencies in non-Hispanic Caucasians. *Genet Med*, 4(2):90-94, 2002. PMID: 11882786.
221. Burke W, Atkins D, Gwinn M, Guttmacher A, Haddow JE, Lau J, Palomaki GE, Press N, Richards CS, Wideroff L, Wiesner GL: Genetic test evaluation: Information needs of clinicians, policy makers, and the public. *Am J Epidemiol*, 156(4):311-318, 2002. PMID: 12181100.
222. Haddow JE: Prenatal screening for Down syndrome: tempering practice with policy. *Ultrasound Obstet Gynecol*, 20(1):103-104, 2002. PMID: 12100435.
223. Wald NJ, Law M, Haddow JE, Craig WY: Apolipoproteins and prediction of fatal myocardial infarction. *Lancet*, 359(9320):1864, 2002. PMID: 12044410.
224. Haddow JE, Palomaki GE, Williams J: Thyroid-stimulating-hormone concentrations and risk of hypothyroidism. *Lancet*, 360(9350):2081-2082, 2002. PMID: 12504442.
225. Palomaki GE, Bradley LA, Richards CS, Haddow JE: Analytic validity of cystic fibrosis testing: A preliminary estimate. *Genet Med*, 5(1):15-20, 2003. PMID: 12544471.
226. Palomaki GE, Neveux LM, Knight GJ, Haddow JE: Maternal serum-integrated screening for trisomy 18 using both first- and second-trimester markers. *Prenat Diagn*, 23(3):243-247, 2003. PMID: 12627428.
227. Mitchell ML, Klein RZ, Sargent JD, Meter RA, Haddow JE, Waisbren SE, Faix JD: Iodine sufficiency and measurements of thyroid function in maternal hypothyroidism. *Clin Endocrinol (Oxf)*, 58(5):612-616, 2003. PMID: 12699443.
228. Haddow JE, Palomaki GE, McClain M, Craig W: Hereditary hemochromatosis and hepatocellular carcinoma in males: a strategy for estimating the potential for primary prevention. *J Med Screen*, 10(1):11-13, 2003. PMID: 12790309.
229. Wald NJ, Morris JK, Rodeck CH, Haddow JE, Palomaki GE: Cystic fibrosis: selecting the prenatal screening strategy of choice. *Prenat Diagn*, 23(6):474-483, 2003. PMID: 12813761.

230. Palomaki GE, Haddow JE, Bradley LA, Richards CS, Stenzel TT, Grody WW: Estimated analytic validity of *HFE* C282Y mutation testing in population screening: the potential value of confirmatory testing. *Genet Med*, 5(6):440-443, 2003. PMID: 14614395.
231. Palomaki GE, Williams J, Haddow JE: Comparing the observed and predicted effectiveness of folic acid fortification in preventing neural tube defects. *J Med Screen*, 10(1):52-53, 2003. PMID: 12790316.
232. Haddow JE: Prenatal screening for cystic fibrosis in the United States - Time to re-evaluate implementation policies. *J Med Screen*, 10(3):105-106, 2003. PMID: 14561259.
233. Haddow JE, Knight GJ, Palomaki GE, McClain MR, Pulkkinen AJ: The reference range and within-person variability of thyroid stimulating hormone during the first and second trimesters of pregnancy. *J Med Screen*, 11(4):170-174, 2004. PMID: 15563772.
234. Palomaki GE, Neveux LM, Knight GJ, Haddow JE, Pandian MR: Maternal serum invasive trophoblastic antigen (ITA) as a screening marker for Down syndrome during the second trimester. *Clin Chem*, 50(10):1804-1808, 2004. PMID: 15319323.
235. Palomaki GE, FitzSimmons SC, Haddow JE: Clinical sensitivity of prenatal screening for cystic fibrosis via *CFTR* carrier testing in a United States panethnic population. *Genet Med*, 6(5):405-414, 2004. PMID: 15371905.
236. McClain MR, Palomaki GE, Haddow JE: Is first trimester measurement of sex hormone binding globulin a possible screening test for gestational diabetes mellitus? *Am J Obstet Gynecol*, 190(6):1808-1809, 2004. PMID: 15290826.
237. McClain MR, Nathanson KL, Palomaki GE, Haddow JE: An evaluation of *BRCA1* and *BRCA2* founder mutations penetrance estimates for breast cancer among Ashkenazi Jewish women. *Genet Med*, 7(1):34-39, 2005. PMID: 15654226.
238. Boyle CA, Ladenson P, Haddow JE: Methods and criteria used in evidence-based decisions in public health. *Thyroid*, 15(1):41-43, 2005. PMID: 15687822.
239. LaFranchi S, Haddow JE, Hollowell JG: Is thyroid inadequacy during gestation a risk factor for adverse pregnancy and developmental outcomes? *Thyroid*, 15(1):60-71, 2005. PMID: 15687825.
240. Hollowell JG, LaFranchi S, Smallridge RC, Spong CY, Haddow JE, Boyle CA: 2004 Where do we go from here? Summary of working group discussions on thyroid function and gestational outcomes. *Thyroid*, 15(1):72-76, 2005. PMID: 15687826.
241. McClain MR, Palomaki GE, Nathanson KL, Haddow JE: Adjusting the estimated proportion of breast cancer cases associated with *BRCA1* and *BRCA2* mutations: public health implications. *Genet Med*, 7(1):28-33, 2005. PMID: 15654225.
242. Haddow JE: Couple screening to avoid thalassemia: successful in Iran and instructive for us all. *J Med Screen*, 12(2):55-56, 2005. PMID: 15949113.
243. Palomaki GE, Knight GJ, Neveux LM, Pandian, R, Haddow JE: Maternal serum invasive trophoblastic antigen (ITA) and first trimester Down syndrome screening. *Clin Chem*, 51(8):1499-1504, 2005. PMID: 15961547.
244. Palomaki GE, Kloza EM, Haddow JE, Williams J, Knight GJ: Patient and health professional acceptance of integrated serum screening for Down syndrome. *Semin Perinatol*, 29(4):247-251, 2005. PMID: 16104676.
245. Knight GJ, Palomaki GE, Neveux L, Smith DE, Kloza EM, Pulkkinen AJ, Williams J, Haddow JE: Integrated serum screening for Down's syndrome in primary obstetric practice. *Prenat Diagn*, 25(12):1162-1167, 2005. PMID: 16231402.
246. Haddow JE: Subclinical hypothyroidism and pregnancy outcomes. *Obstet Gynecol*, 106(1):198, 2005. PMID: 15994654.
247. Haddow JE, Palomaki GE, McClain MR: Thyroid-stimulating hormone in singleton and twin pregnancy: importance of gestational age-specific reference ranges. *Obstet Gynecol*, 107(1):205-206, 2006. PMID: 16394061.
248. Bdolah Y, Palomaki GE, Yaron Y, Bdolah-Abram T, Goldman M, Levine RJ, Sachs BP, Haddow JE, Karumanchi SA: Circulating angiogenic proteins in trisomy 13. *Am J Obstet Gynecol*, 194(1):239-245, 2006. PMID: 16389038.
249. Palomaki GE, Steinort K, Knight GJ, Haddow JE: Comparing three screening strategies for combining first- and second-trimester Down syndrome markers. *Obstet Gynecol*, 107(2 Pt 1):367-375, 2006. PMID: 16449126.

250. Haddow JE, McClain MR, Palomaki GE, Kloza EM, Williams J: Screening for thyroid disorders during pregnancy: results of a survey in Maine. *Am J Obstet Gynecol*, 194(2):471-474, 2006. PMID: 16458648.
251. Palomaki GE, McClain MR, Steinort K, Sifri R, LoPresti L, Haddow JE: Screen positive rates and agreement among six family history screening protocols for breast/ovarian cancer in a cohort of 21- to 55-year-old women. *Genet Med*, 8(3):161-168, 2006. PMID: 16540750.
252. Palomaki GE, Wright DE, Summers AM, Neveux LM, Meier C, O'Donnell A, Huang T, Knight GJ, Haddow JE: Repeated measurement of pregnancy-associated plasma protein-A (PAPP-A) in Down syndrome screening: a validation study. *Prenat Diagn*, 26(8):730-739, 2006. PMID: 16810709.
253. Craig WY, Haddow JE, Palomaki GE, Kelley RI, Kratz LE, Shackleton CHL, Marcos J, Tint GS, Roberson M, MacRae AR, Nowaczyk MJ, Kloza EM, Irons MB: Identifying Smith-Lemli-Opitz syndrome in conjunction with prenatal screening for Down's syndrome. *Prenat Diagn*, 26(9):842-849, 2006. PMID: 16832833.
254. Haddow JE, McClain MR, Palomaki GE, Hollowell JG: Urine iodine measurements, creatinine adjustment and thyroid deficiency in an adult United States population. *J Clin Endocrinol Metab*, 92(3):1019-1022, 2007. PMID: 17200163.
255. Craig WY, Haddow JE, Palomaki GE, Roberson M: Major fetal abnormalities associated with positive screening tests for Smith-Lemli-Opitz Syndrome (SLOS). *Prenat Diagn*, 27(5):409-414, 2007. PMID: 17286308.
256. Palomaki GE, Neveux LM, Knight GJ, Haddow JE, Lee J: Estimating first trimester combined screening performance for Down syndrome in dried blood spots versus fresh sera. *Genet Med*, 9(7):458-463, 2007. PMID: 17666892.
257. Palomaki GE, Neveux LM, Haddow JE, Wyatt P: Hyperglycosylated-hCG (h-hCG) and Down syndrome screening in the first and second trimesters of pregnancy. *Prenat Diagn*, 27(9):808-813, 2007. PMID: 17590886.
258. Shackleton CHL, Marcos J, Palomaki GE, Craig WY, Kelley RI, Kratz LE Haddow JE: Dehydrosteroid measurements in maternal urine or serum for the prenatal diagnosis of Smith-Lemli-Opitz syndrome (SLOS). *Am J Hum Genet Part A*, 143A(18):2129-2136, 2007. PMID: 17702049.
259. Bradley LA, Kloza EM, Haddow PK, Beauregard LJ, Johnson JL, Haddow JE: A genetic history questionnaire-based system in primary care to screen for selected fetal disorders. *Genet Test*, 11(3):291-295, 2007. PMID: 17949290.
260. Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. *Genet Med*, 9(12):819-825, 2007. PMID: 18091431.
261. Hollowell JG, Haddow JE: The prevalence of iodine deficiency in women of reproductive age in the United States of America. *Public Health Nutr*, 10(12A):1532-1539, 2007. PMID: 18053275.
262. McClain MR, Palomaki GE, Haddow JE: How reliable are *BRCA1/2* mutation estimates? *Cancer Res*, 67(10):5057, 2007. PMID: 17510441.
263. Palomaki GE, Neveux LM, Donnenfeld A, Lee J, McDowell G, Canick JA, Summers A, Lambert-Messerlian G, Kellner L, Zebelman A, Haddow JE: Quality assessment of routine nuchal translucency measurements: a North American laboratory perspective. *Genet Med*, 10(2):131-138, 2008. PMID: 18281921.
264. McClain MR, Palomaki GE, Hampel H, Westman JA, Haddow JE: Screen positive rates among six family history screening protocols for breast/ovarian cancer in four cohorts of women. *Fam Cancer*, 7(4):341-345, 2008. PMID: 18207415.
265. McClain MR, Palomaki GE, Piper M, Haddow JE: A Rapid ACCE review of *CYP2C9* and *VKORC1* allele testing to inform initial warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. *Genet Med*, 10(2):89-98, 2008. PMID: 18281915.
266. Lambert-Messerlian G, McClain MR, Haddow JE, Palomaki GE, Canick JA, Cleary-Goldman J, Malone FD, Porter TF, Nyberg DA, Gross SJ, D'Alton ME: First- and second-trimester thyroid hormone reference data in pregnant women: a FaSTER (First and Second Trimester Evaluation of Risk for aneuploidy) Research Consortium study. *Am J Obstet Gynecol*, 199(1):62.e1-6, 2008. PMID: 18585522.

- 267.
268. Haddow JE, McClain M, Lambert-Messerlian G, Palomaki GE, Canick JA, Cleary-Goldman J, Malone FD, Porter TF, Nyberg DA, Bernstein P, D'Alton ME: Variability in TSH Suppression by hCG During Early Pregnancy: A FaSTER (First and Second Trimester Evaluation of Risk for Fetal Aneuploidy) trial study. *J Clin Endocrinol Metab*, 93(9):3341-3347, 2008. PMID: 18544616.
269. McClain MR, Lambert-Messerlian G, Haddow JE, Palomaki GE, Canick JA, Cleary-Goldman J, Malone FD, Porter TF, Nyberg DA, Bernstein P, D'Alton ME: Sequential first and second trimester TSH, T4, and thyroid antibody measurements in women with known hypothyroidism: a FaSTER (First and Second Trimester Evaluation of Risk for Fetal Aneuploidy) trial study. *Am J Obstet Gynecol*, 199(2):129.e1-129.e6, 2008. PMID: 18448078.
270. Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, Dotson WD, Douglas MP, Berg AO: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: Methods of the EGAPP Working Group. *Genet Med*, 11(1):3-14, 2009. PMID: 18813139.
271. Recommendations from the EGAPP Working Group: Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? *Genet Med*, 11(1):15-20, 2009. PMID: 18813140.
272. Recommendations from the EGAPP Working Group: Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. *Genet Med*, 11(1):35-41, 2009. PMID: 19125126.
273. Marcos J, Craig WY, Palomaki GE, Kloza EM, Haddow JE, Roberson M, Bradley LA, Shackleton CHL: Maternal urine and serum steroid measurements to identify steroid sulfatase deficiency (STSD) in second trimester pregnancies. *Prenat Diagn*, 29(8):771-780, 2009. PMID: 19418464.
274. Botkin JR, Teutsch SM, Kaye CI, Hayes M, Haddow JE, Bradley LA, Szegda K, Dotson WD; on behalf of the EGAPP Working Group. Outcomes of interest in evidence-based evaluations of genetic tests. *Genet Med*, 12(4):228-235, 2010. PMID: 20118789.
275. Palomaki GE, Knight GJ, Lambert-Messerlian G, Canick JA, Haddow JE: Four years experience with an inter-laboratory comparison program involving first trimester markers of Down syndrome. *Arch Pathol Lab Med*, 134(11):1685-1691, 2010. PMID: 21043823.
276. Haddow JE, Cleary-Goldman J, McClain MR, Palomaki GE, Neveux LM, Lambert-Messerlian G, Canick JA, Malone FD, Porter TF, Nyberg DA, Bernstein PS, D'Alton ME: Thyroperoxidase and thyroglobulin antibodies in early pregnancy and pre-term delivery. *Obstet Gynecol*, 116(1):58-62, 2010. PMID: 20567168.
277. Craig WY, Roberson M, Palomaki GE, Shackleton CHL, Marco J, Haddow JE: Prevalence of steroid sulfatase deficiency according to race and ethnicity. *Prenat Diagn*, 30(9):893-898, 2010. PMID: 20715120.
278. Recommendations from the EGAPP Working Group: Genomic profiling to assess cardiovascular risk to improve cardiovascular health. *Genet Med*, 12(12):839-843, 2010. PMID: 21042222.
279. Haddow JE: Hypothyroidism: detecting and treating early symptoms as the body's energy rheostat is slowly turned down. *J Med Screen*, 17(4):163, 2010. PMID: 21258124.
280. Recommendations from the EGAPP Working Group: Routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members. *Genet Med*, 13(1):67-76, 2011. PMID: 21150787.
281. Haddow JE, McClain MR, Palomaki GE, Neveux LM, Lambert-Messerlian G, Canick JA, Malone FD, Porter TF, Nyberg DA, Bernstein PS, D'Alton ME for the First and Second Trimester Risk of Aneuploidy (FaSTER) Research Consortium: Thyroperoxidase and thyroglobulin antibodies in early pregnancy and placental abruption. *Obstet Gynecol*, 117(2 Pt 1):287-292, 2011. PMID: 21252741.
282. Craig WY, Palomaki GE, Roberson M, Haddow JE: Further insights into implications of undetectable or very low unconjugated estriol in maternal serum during the second trimester. *Prenat Diagn*, 31(6):616-618, 2011. PMID: 21472738.
283. Haddow JE, Neveux LM, Palomaki GE, Lambert-Messerlian G, Canick JA, Grenache DG, Lu J: The relationship between PTH and 25-hydroxy vitamin D in pregnancy. *Clin Endocrinol (Oxf)*, 75(3):309-314, 2011. PMID: 21521334.
284. Haddow JE: Vitamin D and rickets: Much has been accomplished, but there is still room for improvement. *J Med Screen*, 18(2):58-59, 2011. PMID: 21852696.

285. Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, van den Boom D, Bombard AT, Deciu C, Grody WW, Nelson SF, Canick JA: DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation study. *Genet Med*, 13(11):913-920, 2011. PMID: 22005709.
286. Haddow JE, Palomaki GE: Screening to detect Lynch syndrome and prevent hereditary cancers in relatives. *J Med Screen*, 18(4):167-168, 2011. PMID: 22184732.
287. Haddow JE: Folic acid and neural tube defects. *Genet Med*, 13(9):849, 2011. PMID: 21885925.
288. Haddow JE: The New American Thyroid Association Guidelines for thyroid disease during pregnancy and postpartum: a blueprint for improving prenatal care. Invited Editorial. *Thyroid*, 21(10):1047-1048, 2011. PMID: 21943133.
289. Craig WY, Allan WC, Kloza EM, Pulkkinen AJ, Waisbren S, Spratt DI, Palomaki GE, Neveux LM, Haddow JE: Mid-gestational maternal free thyroxine concentration and offspring neurocognitive development at age two years. *J Clin Endocrinol Metab*, 97:E22-E28, 2012. PMID: 22031521.
290. Palomaki GE, Deciu C, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, van den Boom D, Bombard AT, Grody WW, Nelson SF, Canick JA: DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. *Genet Med*, 14(3):296-305, 2012. PMID: 22281937.
291. Canick JA, Kloza EM, Lambert-Messerlian GM, Haddow JE, Ehrich M, van den Boom D, Bombard AT, Deciu C, Palomaki GE: DNA sequencing of maternal plasma to identify Down syndrome and other trisomies in multiple gestations. *Prenat Diagn*, 32(8):730-734, 2012. PMID: 22585317.
292. Gronowski AM, Haddow J, Kilpatrick S, Lazarus JH, Negro R: Thyroid function during pregnancy: Who and how should we screen? *Clin Chem*, 58:1397-1401, 2012. PMID: 22675197.
293. Wald NJ, Haddow JE: The Canadian recommendations on screening for type 2 diabetes. *J Med Screen*, 19(4):163, 2012 (editorial). PMID: 23486696.
294. Veenstra DL, Piper M, Haddow JE, Pauker SG, Klein R, Richards CS, Tunis SR, Djulbegovic B, Marone M, Lin JS, Berg AO, Calonge N, on behalf of the EGAPP Working Group: Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update. *Genet Med*, 15(1):14-24, 2013. PMID: 22955111.
295. Haddow JE, Craig WY, Palomaki GE, Neveux LM, Lambert-Messerlian G, Canick JA, Malone FD, D'Alton ME: Impact of adjusting for the reciprocal relationship between maternal weight and free thyroxine during early pregnancy. *Thyroid*, 23(2):225-230, 2013. PMID: 23136959.
296. Evaluation of Genomic Applications in Practice and Prevention Working Group: Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? *Genet Med*, 15(7):517-527, 2013. PMID: 23429431.
297. Haddow JE: Maternal thyroxine and fetal brain development: The latest chapter, a look back, and considerations for the future. *J Clin Endocrinol Metab*, 98(4):1388-1390, 2013. PMID: 23564943.
298. Canick JA, Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE: The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies. *Prenat Diagn*, 33(7):667-674, 2013. PMID: 23592541.
299. Palomaki GE, Knight GJ, Ashwood ER, Best RG, Haddow JE: Screening for Down syndrome in the United States: Results of surveys in 2011 and 2012. *Arch Pathol Lab Med*, 137(7):921-926, 2013. PMID: 23808464.
300. Craig WY, Palomaki GE, Neveux LM, Haddow JE: Maternal body mass index during pregnancy and offspring neurocognitive development. *Obstet Med*, 6(1):20-25, 2013. PMID: 27757147.
301. Haddow JE, Craig WY, Neveux LM, Haddow RMH, Palomaki GE, Lambert-Messerlian G, Malone FD, D'Alton ME: Implications of high free thyroxine (FT4) concentrations in euthyroid pregnancies: The FaSTER Trial. *J Clin Endocrinol Metab*, 99(6):2038-2044, 2014. PMID: 24606107.
302. Palomaki G, Kloza E, Lambert-Messerlian G, van den Boom D, Ehrich M, Deciu C, Bombard A, Haddow J: Circulating cell free (ccf) DNA testing: are some test failures informative? *Prenat Diagn*, 35(3):289-293, 2015. PMID: 25449554.

303. Palomaki GE, Haddow JE, Haddow HR, Salahuddin S, Geahchan C, Cerdeira AS, Verlohren S, Perschel FH, Horowitz G, Thadhani R, Karumanchi SA, Rana S. Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia. *Prenat Diagn*, 35(4):386-393, 2015. PMID: 25641027.
304. Haddow JE, Neveux LM, Palomaki GE, Lambert-Messerlian G, Malone FD, D'Alton ME: An inverse relationship between weight and free thyroxine during early gestation among women treated for hypothyroidism. *Thyroid*, 25(8):949-953, 2015. PMID: 26061605.
305. Haddow JE, Craig WY, Neveux LM, Palomaki GE, Lambert-Messerlian G, Malone FD, D'Alton ME: Free thyroxine during early pregnancy and risk for gestational diabetes. *PLoS One*, 11(2):e0149065, 2016. PMID: 26910563.
306. Palomaki GE, Haddow JE: Confusion between analytic validity and clinical validity. *Am J Obstet Gynecol*, 215(4):533-534, 2016. PMID: 27316786.
307. Palomaki GE, Lambert-Messerlian G, Haddow JE: Where have all the trisomies gone? *Am J Obstet Gynecol*, 215(5):583-587.e1, 2016. PMID: 27793310.

OTHER PEER-REVIEWED ARTICLES:

1. Haddow JE, Lester R: Mechanism of action of spironolactone in preventing mercury toxicity. *Gastroenterology*, 64:159, 1973.
2. Haddow JE: Ethical problems of screening for neural tube defects. *Lancet*, ii:527, 1978.
3. Haddow JE, Smith DE, Sever J: Effect of maternal weight on maternal serum alpha-fetoprotein. *Br J Obstet Gynaecol*, 89:93, 1982.
4. Palomaki GE, Knight GJ, Haddow JE: Screening for Down's syndrome. *N Engl J Med*, 318:928, 1988.
5. Haddow JE, Knight GJ, Palomaki GE, McCarthy JE, Foss KC: Serum cotinine levels in pregnant nonsmokers in relation to birthweight. *Ann NY Acad Sci*, 562:370-371, 1989.
6. Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T, Haddow JE, Knight GJ, Palomaki GE, Canick JA: Serum screening for Down's syndrome. *BMJ*, 298:50, 1989.
7. Haddow JE, Palomaki GE, Chilmonczyk BA: Hazards of active and passive smoking. *N Engl J Med*, 329(21):1580-1581, 1993.
8. Palomaki GE, Haddow JE: Can the risk for Down syndrome be reliably modified by second trimester ultrasound? *Am J Obstet Gynecol*, 173:1639-1640, 1995.
9. Haddow JE: Screening Brief: Cystic Fibrosis. *J Med Screen*, 3:55, 1996.
10. Palomaki GE, Haddow JE: Prenatal serum markers and trisomy 18. *Prenat Diagn*, 16(5):477-478, 1996.
11. Haddow JE, Palomaki GE: Down's syndrome screening. *Lancet*, 347:1625, 1996.
12. Haddow JE: Antenatal serum screening for neural-tube defects. *Gynaecology Forum*, 2:7-12, 1997.
13. Bradley LA, Haddow, JE: Screening brief: Hereditary haemochromatosis. *J Med Screen*, 4:248, 1997.
14. Haddow JE, Palomaki GE, Knight GJ, Bradley LA, Doherty RA: Screening for cystic fibrosis. *JAMA*, 279(14):1068, 1998.
15. Palomaki GE, Knight GJ, Neveux LM, Haddow JE, Pandian R: First-trimester Down syndrome screening (Response to Hallahan). *Clin Chem*, 52:161, 2006.

BOOKS AND BOOK CHAPTERS:

1. Klein R, Haddow JE: Hyperparathyroidism. *In: Endocrine and Genetic Diseases of Childhood*, 2nd Edition, Gardner LI (ed.), W.B. Saunders Co., Philadelphia & London, 1975.
2. Screening for Neural Tube Defects in the United States: Proceedings of the First Scarborough Conference. Haddow JE, Macri JN (eds). Published at Scarborough, Maine, by the Foundation for Blood Research, June, 1978.
3. Haddow JE: Informed consent and patient education. p. 24; Haddow JE: A pilot project aimed at developing statewide prenatal neural tube defect screening in Maine - Introduction, p. 113; Haddow JE: A projected analysis of costs in the Maine neural tube defect screening program, p. 129. *In: Screening for Neural Tube Defects in the United States: Proceedings of the First Scarborough Conference*, 1978.

4. Alpha-fetoprotein Serum Screening in Pregnancy: Proceedings of the Second Scarborough Conference. Haddow JE, Macri JN (eds). Published at Scarborough, Maine by the Foundation for Blood Research, May, 1979.
5. Haddow JE: Amniotic fluid proteins in relation to low birthweight/prematurity, p. 166. *In*: Alpha-fetoprotein Serum Screening in Pregnancy: Proceedings of the Second Scarborough Conference. Edited by J.E. Haddow and J.N. Macri. Published at Scarborough, Maine by the Foundation for Blood Research, May, 1979.
6. Haddow JE, Ritchie RF: Newer immunochemical techniques for the quantification of specific proteins. *In*: Recent Advances in Clinical Immunology, No. 2, RA Thompson, (ed.), Churchill Livingstone, (Edinburgh), pp. 293-311, 1980.
7. Milunsky A, Wald NJ, Brock DJH, Dallaire L, Davidson R, Ferguson-Smith MA, Fuhrmann W, Haddow JE, Macri J, Winsor E. Prenatal screening and diagnosis of open neural-tube defects. *Prenat Diagn* (Special Issue), Prenatal Diagnosis - Past, Present and Future (Report of an International Workshop), 1980.
8. Maternal Serum Alpha-Fetoprotein. Issues in the Prenatal Screening and Diagnosis of Neural Tube Defects. Proceedings of a Conference held by the National Center for Health Care Technology and the Food and Drug Administration, July 28-30, 1980, Washington, D.C. Gastel B, Haddow JE, Fletcher JC, Neale A (eds), U.S. Government Printing Office.
9. Alpha-fetoprotein Screening: The Current Issues. A Report of the Third Scarborough Conference. Haddow JE, Wald NJ (eds). Published at Scarborough, Maine, by the Foundation for Blood Research, 1981.
10. Haddow JE: Proteins in Amniotic Fluid: Diagnostic and Clinical Considerations, with Special Emphasis on Alpha-Fetoprotein. *In*: Proteins in Body Fluids, Amino Acids, and Tumor Markers: Diagnostic and Clinical Aspects. Alan R. Liss, Inc., New York, pp. 173-185, 1983.
11. Haddow JE: Alpha-Fetoprotein. *In*: Assessment of the National Effort to Combat Mental Retardation from Biomedical Causes. Conference Proceedings, November 14-16, 1983. U.S. Department of Health and Human Services, Washington, DC, pp. 96-98, 1983.
12. Haddow JE, Goldfine C: The Evolving Role of Amniotic Fluid Acetylcholinesterase Analysis for Identifying Open Fetal Defects During the Second Trimester. *In*: Alpha-fetoprotein and Congenital Disorders. Academic Press, Inc., San Diego, California, pp. 215-237, 1985.
13. Haddow JE, Haddow PK: Passive Exposure to Cigarette Smoke Adversely Affects the Health of Fetuses and Infants. *In*: Developmental Handicaps: Prevention and Treatment IV. American Association of University Affiliated Programs. Silver Spring, MD, pp. 1-14, 1987.
14. Haddow JE: Prenatal Diagnosis of Neural Tube Defects. *In*: Fetal and Neonatal Neurology and Neurosurgery. Levene MI, Bennett MJ, Punt J (eds.). Churchill Livingstone, London, pp. 279-289, 1988.
15. Knight GJ, Palomaki GE, Haddow JE: Use of Maternal Serum Alpha-fetoprotein Measurements to Screen for Down's Syndrome. *In*: 1988 Clinical Obstetrics and Gynecology Symposium on Prenatal Diagnosis. Williamson RA (ed), J.B. Lippincott Company, 306-327, 1988.
16. Haddow JE: Alpha-fetoprotein. *In*: The Unborn Patient. Prenatal Diagnosis and Treatment. Second Edition. Harrison MR, Golbus MS, Filly RA (eds.), W.B. Saunders Company, pp. 63-74, 1990.
17. Haddow JE, Palomaki GE, Knight GJ, Kloza EM, Hitchcock J: Prenatal Screening for Major Fetal Disorders. Vol. I: Fetal Disorders Associated with Elevated MSAFP Values. Haddow JE (ed), published at Foundation for Blood Research, 1990.
18. Haddow JE, Palomaki GE: Maternal Protein Enzyme Analyses. *In*: Medicine of the Fetus & Mother. Reece EA, Hobbins JC, Mahoney MJ, Petrie RH (eds.), J.B. Lippincott Company, pp. 653-667, 1992.
19. Haddow JE: Biologic Properties of Alpha-Fetoprotein in Detection of Fetal Disorders. *In*: Maternal Serum Screening for Fetal Genetic Disorders. Elias S, Simpson JL (eds.), Churchill Livingstone, pp. 25-40, 1992.
20. Haddow JE, Knight GJ, Palomaki GE: Measuring serum cotinine to aid in smoking cessation during pregnancy and to enhance assessment of smoking-related fetal morbidity. *In*: Effects of Smoking on the Fetus, Neonate, and Child. Poswillo D, Alberman E (eds.), Oxford University Press, pp. 207-222, 1992.
21. Haddow JE, Palomaki GE: Prenatal Screening for Down Syndrome. *In*: Essentials of Prenatal Diagnosis. Simpson JL, Elias S (eds.), Churchill Livingstone, pp. 185-220, 1993.

22. Haddow JE: Prenatal screening for Down syndrome. *In: Protocols for High-Risk Pregnancies.* Queenan JT, Hobbins JC (eds), Third Edition, pp. 68-74, 1995.
23. Knight GJ, Palomaki GE, Haddow JE: Alpha-fetoprotein screening for neural tube defects. *In: When to Screen in Obstetrics & Gynecology.* W.B. Saunders Co., Ltd., Wildschut HIJ, Weiner CP, Peters TJ (eds.), pp. 72-80, 1996.
24. Knight GJ, Palomaki GE, Haddow JE: Triple marker screening for fetal Down syndrome. *In: When to Screen in Obstetrics & Gynecology.* Wildschut HIJ, Weiner CP, Peters TJ (eds.), W.B. Saunders Co., Ltd., pp. 80-87, 1996.
25. Haddow JE: Assessing the Performance of Screening and Diagnostic Tests. *In: Genetic Services: Developing Guidelines for the Public's Health.* Freeman SB, Hinton CF, Elsas LJ (eds.), Council of Regional Networks for Genetic Services, Atlanta, GA, pp. 180-184, 1996.
26. Haddow JE, Palomaki GE: Biochemical Screening for Neural Tube Defects and Down Syndrome. *In: Fetal Medicine: Basic Science and Clinical Practice.* Rodeck CH, Whittle MJ (eds), Churchill Livingstone: London, 373-388, 1999.
27. Haddow JE, Palomaki GE: Biochemical Markers of Fetal Disorders in Maternal Serum and Amniotic Fluid. *In: Medicine of the Fetus & Mother, Second Edition.* Reece EA, Hobbins JC (eds.), J.B. Lippincott Company, pp. 689-706, 1999.
28. Haddow JE: Medical Screening: Assuring Scientific and Ethical Soundness as a Prelude to Economic Analysis. *In: Down Syndrome: Screening Policy and Economic Evaluations.* Beazoglou T, Benn P, Cuckle H, Haddow JE, Kryiopoulos J (eds.), Exandas Publishers, pp. 15-28, 1999.
29. Richards CS, Haddow JE: Prenatal Screening for Cystic Fibrosis. *In: Clinics in Laboratory Medicine. Prenatal Testing.* Canick J, Lambert-Messerlian G (eds.), W.B. Saunders Company, Vol. 23, No. 2, pp. 503-530, 2003.
30. Haddow JE, Palomaki GE: ACCE: A Model Process for Evaluating Data on Emerging Genetic Tests. *In: Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease.* Khoury M, Little J, Burke W (eds.), Oxford University Press, pp. 217-233, 2003.
31. Palomaki GE, McClain MR, Haddow JE. ACCE reviews of genetic tests: *BRCA1*, *BRCA2*, and *CFTR*. *In: Genomics and Population Health: United States 2005.* Centers for Disease Control and Prevention, Office of Genomics and Disease Prevention. Atlanta, Georgia, 2005, pp. 27-33.
32. Haddow JE, Palomaki GE, Wapner RJ: First- and second-trimester screening for open neural tube defects and Down syndrome. Chapter 28. *In: Clinical Obstetrics: the Fetus & Mother Handbook.* Reece EA, Hobbins JC, (eds), 3rd Edition, Blackwell Publishing Ltd, pp. 485-503, 2007.
33. Haddow JE, Palomaki GE, Canick JA, Knight GJ: Prenatal screening for open neural tube defects and Down's syndrome. *In: Fetal Medicine: Basic Science and Clinical Practice.* Rodeck CH, Whittle MJ (eds), Churchill Livingstone: London, 243-264, 2009.
34. Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, Dotson WD, Douglas MP, Berg AO: The evaluation of genomic applications in practice and prevention (EGAPP) initiative: Methods of the EGAPP working group. *In: Human Genome Epidemiology, 2nd Edition.* Khoury MJ, Bedrosian SR, Gwinn ML, Higgins JPT, Ioannidis JPA, Little J (eds). Oxford University Press, pp. 458-481, 2010.
35. McClain MR, Palomaki GE, Piper M, Haddow JE: A Rapid-ACCE Review of *CYP2C9* and *VKORC1* allele testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. *In: Human Genome Epidemiology, 2nd Edition.* Khoury MJ, Bedrosian SR, Gwinn ML, Higgins JPT, Ioannidis JPA, Little J (eds). Oxford University Press, pp. 620-638, 2010.

NON-PEER REVIEWED PUBLICATIONS:

1. Haddow JE: Alpha-fetoprotein Serum Screening in Pregnancy. Check Sample Exercise for American Society of Clinical Pathologists, 1980.
2. Haddow JE, Reimer C: Guidelines for Standards to Assist the Quality of Systems for Alpha-fetoprotein (AFP) Assay in Prenatal Diagnosis. NCCLS Committee Document, Final Copy, July, 1980.

3. Haddow JE, Brewster TG: The frequency of identifiable fetal malformations in pregnant women with diabetes. Perinatal Report, Department of Obstetrics and Gynecology, Maine Medical Center, June, 1982.
4. Haddow JE, Thompson DK: Serum proteins in malignancy. Specific Protein Analysis. American Association for Clinical Chemistry, Vol. 1, No. 17, January, 1984.
5. Haddow JE: Can second trimester maternal serum alpha-fetoprotein (MSAFP) measurements be used to screen for Down syndrome? *The Genetic Resource*, Massachusetts Department of Public Health, p 5, Autumn 1984.
6. Haddow JE: Smoking in Pregnancy: A new approach to solving a continuing problem. *The Genetic Resource*, Massachusetts Department of Public Health, p. 9, Winter, 1985.
7. Haddow JE, Knight GJ: Maternal serum alpha-fetoprotein screening: A test for the dedicated laboratory. *J Med Tech*, 3:477, 1986.
8. Haddow JE: Assuring quality in maternal serum alpha-fetoprotein (MSAFP) screening. *The Genetic Resource*, Massachusetts Department of Public Health, p. 20, Autumn 1985-Winter, 1986.
9. Anderson B, Cassidy S, Green S, Haddow JE, Kloza EM, Schoenfeld M: Low maternal serum alpha-fetoprotein and Down syndrome: Information for physicians. *The Genetic Resource*, Massachusetts Department of Public Health, p. 24, Autumn 1985-Winter 1986.
10. Knight GJ, Palomaki GE, Haddow JE: Assessing reliability of AFP test kits. *Contemp OB/GYN*, 30:37-52, 1987.
11. Knight GJ, Haddow JE, Palomaki GE, Canick JA: Modification of an unconjugated estriol kit for Down syndrome screening in the second trimester of pregnancy. *Clin Chem*, 34:1206, 1988.
12. Haddow JE: MSAFP Screening: Is there a need for regulation? *Clin Chem Newsletter*, 3:3, 1988.
13. Haddow JE, Palomaki GE, Knight GJ, Williams J, Pulkkinen A, Canick JA, Saller DN, Bowers GB: Dépistage prénatal de la trisomie 21 a l'aide de marqueurs sériques maternels. *Journal International de Médecine*, 248:33-40, 1992.
14. Haddow JE: Thyroid deficiency in pregnancy: frequency, seriousness, plan of action. *OBG Management*, 12:14-25, 2000.
15. Haddow JE, Palomaki GE: An introduction to assessing genomic screening and diagnostic tests. *Nutr Today*, 46:162-168, 2011.
16. Haddow JE: Preventing, identifying and managing thyroid deficiency in prenatal practice. *Expert Rev Obstet Gynecol*, 8:213-222, 2013.

CORPORATE AUTHORSHIP OR MULTICENTER TRIALS:

1. Amniotic fluid acetylcholinesterase electrophoresis as a secondary test in the diagnosis of anencephaly and open spina bifida in early pregnancy. *Lancet*, ii:321, 1981.
2. Effects of neonatal screening for hypothyroidism: Prevention of mental retardation by treatment before clinical manifestations. *Lancet*, ii:1095, 1981.
3. Maternal serum prostate-specific antigen and Down syndrome in the first and second trimesters of pregnancy. *Prenat Diagn*, 19:674-676, 1999.
4. SP1 in pregnancies with Down's syndrome in the first trimester of pregnancy. *Prenat Diagn*, 19:517-520, 1999.

PUBLICATIONS SUBMITTED OR IN PREPARATION:

ABSTRACTS (represents partial list):

1. Page L, Haddow JE: Adrenal 3beta-hydroxysteroid dehydrogenase enzyme defect. Proc. Second Annual Maine Biomed. Symposium, July 8-10, 1976.
2. Haddow JE, Barbarow B, Aldrich N: Development of the alpha₁-fetoprotein assay for diagnosing fetal neural tube defects. Proc. Second Annual Maine Biomed. Symposium, July 8-10, 1976.
3. Thompson DK, Haddow JE: Serial monitoring of alpha₁-fetoprotein in selective tumors. Proc. Second Annual Maine Biomed. Symposium, July 8-10, 1976.
4. Stevens J, Ritchie RF, Haddow JE: A pregnancy-associated protein with potential use in cancer diagnosis. Proc. Second Annual Maine Biomed. Symposium, July 8-10, 1976.

5. Chute A, Augur E, Dubeau A, Haddow JE: Laboratory analysis of hemophilia A carriers in Maine. Proc. Second Annual Maine Biomed. Symposium, July 8-10, 1976.
6. Haddow JE, Macri JN, Munson ME, Baldwin P, Ritchie RF: The second trimester normal amniotic fluid protein levels as determined in the automated immunoprecipitin system. Proc. Seventh Technicon International Congress, December 13-15, 1976.
7. Hostetter MK, Levy HL, Haddow JE: Alpha-fetoprotein (AFP) elevation preceding hypertyrosinemia in hereditary tyrosinemia. *Soc Pediat Res*, April, 1980.
8. Haddow JE, Miller WA: False positive alpha-fetoprotein (AFP) values in amniotic fluid samples - how many lead to termination. The American Society of Human Genetics, 31st Annual Meeting, New York City, September 24-27, 1980.
9. Goldfine C, Haddow JE, Hudson GA, Miller WA: Prenatal diagnosis of neural tube defects: Gel acetylcholinesterase analysis combined with densitometry. The American Society of Human Genetics, 32nd Annual Meeting, Dallas, Texas, October, 1981.
10. Goldfine CC, Miller WA, Haddow JE: Characterization of open fetal lesions by their gel cholinesterase densities. The American Society of Human Genetics, 33rd Annual Meeting, 1982.
11. Haddow JE, Goldfine C: The evolving role of amniotic fluid acetylcholinesterase analysis for identifying open fetal defects during the second trimester. The National Foundation -- March of Dimes Annual Meeting, Albany, New York, October, 1983.
12. Knight GJ, Haddow JE, Palomaki GE, Kloza EM: Cotinine vs. self-reported cigarette consumption as predictors of birthweight (APS-SPR Meeting), May 6-9, 1985.
13. Haddow JE, Hill LE, Kloza EM, Thanhauser D: Neural tube defects following gastric bypass procedures. 7th International Congress of Human Genetics, W. Berlin, September 22-26, 1986.
14. Knight GJ, Palomaki GE, Holman MS, Haddow JE: External quality assessment of laboratories performing AFP screening. American Public Health Association, 114th Annual Meeting. Las Vegas, Nevada, September 28-October 2, 1986.
15. Biber A, Scherer G, Hoepfner I, Adlkofer F, Haddow JE, Knight GJ: Determination of nicotine and cotinine in human serum and urine: An interlaboratory study. International Exp. Toxicology Symposium on Passive Smoking, Essen, West Germany, October 23-25, 1986.
16. Canick JA, Knight GJ, Palomaki GE, Haddow JE, Cuckle HS, Wald NJ: Low second trimester maternal serum unconjugated estriol in Down syndrome pregnancies. *Am J Hum Genet Suppl*, 41:a269, 1987.
17. Canick JA, Sung J, Singer DB, Knight GJ, Palomaki GE, Haddow JE, Cuckle HS, Wald NJ: Second trimester maternal serum estriol, progesterone, SP1, and alpha-fetoprotein in Down syndrome pregnancy: Relationship to fetal adrenal, fetal liver, and placental mass. Endocrine Society Meeting, 1988.
18. Steinort K, Knight GJ, Haddow JE, Palomaki GE: Biochemical measurements and passive tobacco smoke exposure. Fourteenth Annual Maine Biological and Medical Symposium, May, 1988.
19. Klein RZ, Haddow JE, Faix JD, Brown RS, Pulkkinen A, Mitchell ML: Incidence of thyroid deficiency in pregnancy. 10th International Thyroid Congress, Jerusalem, Israel, Abstract, 1990.
20. Chilmonczyk BA, Knight GJ, Williams J, Pulkkinen AJ, Palomaki GE, Haddow JE: Urinary cotinine to evaluate passive smoke exposure in infancy. Society for Pediatric Research, 1989.
21. Greenberg F, Faucett WA, Rose E, Alpert E, Bancalari L, Kardon NB, Mizjewski G, Knight GJ, Haddow JE: Congenital deficiency of alpha-fetoprotein. Society for Pediatric Research, 1989.
22. Johnson AM, Palomaki GE, Haddow JE: Adjustment of maternal serum alpha-fetoprotein (MSAFP) levels for race and for maternal weight in screening for fetal open spina bifida: A United States collaborative study. American Society of Human Genetics, November 12-15, 1989.
23. Canick JA, Stevens LD, Abell KB, Panizza DS, Osathanondh R, Knight GJ, Palomaki GE, Haddow JE: Second trimester maternal serum unconjugated estriol and human chorionic gonadotropin in pregnancies affected with fetal Trisomy 18, anencephaly, and open spina bifida. American Society of Human Genetics, November 12-15, 1989.
24. Haddow JE, Foss KC, Knight GJ, Blitzer MG, Fenske M: The significance of very faint pseudocholinesterase bands in amniotic fluid samples analyzed by gel electrophoresis. American Society of Human Genetics, November 12-15, 1989.

25. Knight GJ, Palomaki GE, Haddow JE, Johnson AM, Osathanondh R, Canick JA: Maternal serum levels of the placental products hCG, hPL, SP1, and progesterone are all elevated in cases of fetal Down syndrome. American Society of Human Genetics, November 12-15, 1989.
26. Donnenfeld AE, Pulkkinen AJ, Palomaki GE, Knight GJ, Haddow JE: Serum cotinine levels in non-pregnant adult smokers, pregnant mothers who smoke, and exposed fetuses. American Society of Human Genetics, November 12-15, 1989.
27. Faucett WA, Greenberg F, Rose E, Alpert E, Bancalari L, Kardon NB, Mizjewski G, Knight G, Haddow JE: Congenital deficiency of alpha-fetoprotein. American Society of Human Genetics, November 12-15, 1989.
28. Knight GJ, Haddow JE, Palomaki GE: Epidemiological studies of smoking and birthweight using a biochemical marker. Bingham Consortium for Health Research, October, 1989.
29. Haddow JE, Hitchcock JL, Knight GJ, Kloza EM, Palomaki GE, Wald NJ: Cotinine-assisted intervention with smoking by pregnant women. Bingham Consortium for Health Research, October, 1989.
30. Palomaki GE, Haddow JE, Knight GJ: Maternal serum screening for Down syndrome in early pregnancy. Bingham Consortium for Health Research, October, 1989.
31. Craig WY, Palomaki GE, Haddow JE: Cigarette smoking and serum lipid and lipoprotein levels in adults and in the 8-19 year age group: An analysis of published data. Bingham Consortium for Health Research, October, 1989.
32. Klein RZ, Haddow JE, Faix JD, Brown RS, Pulkkinen A, Mitchell ML: Incidence of thyroid deficiency in pregnancy. The American Pediatric Society, Abstract, 1990.
33. Haddow JE, Palomaki GE, Knight GJ, Williams JR, Beauregard LJ: The effect of maternal weight adjustment on screening for Down syndrome using maternal serum alpha-fetoprotein and age. *Am J Hum Genet*, 49(Suppl):222, 1991.
34. Palomaki GE, Knight GJ, Haddow JE, Canick JA, Saller DN, Panizza DS, Grant SS, Wenstrom KD, Hudson JD: Prospective trial of a screening protocol to identify Trisomy 18 using maternal serum alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin. 8th International Congress of Human Genetics, *Am J Hum Genet*, 49(Suppl):227, 1991.
35. Beauregard LJ, Palomaki GE, Williams JR, Haddow JE: The pattern of prenatal screening and diagnosis of Down syndrome in Maine: 1980 to 1989. 8th International Congress of Human Genetics, *Am J Hum Genet*, 49(Suppl):210, 1991.
36. Rose NC, Palomaki GE, Haddow JE, Giardine R, Mennuti MT: The effect of maternal weight adjustment on MSAFP screening for Down syndrome in women age 35 and older. 8th International Congress of Human Genetics, *Am J Hum Genet*, 49(Suppl):216, 1991.
37. Rose NC, Palomaki GE, Haddow JE, Senior M, Mennuti MT: The effect of maternal race on maternal serum and amniotic fluid alpha-fetoprotein (AFP) measurements. 8th International Congress of Human Genetics, *Am J Hum Genet*, 49(Suppl):225, 1991.
38. Rose NC, Palomaki GE, Haddow JE, Mennuti MT: Maternal serum alpha-fetoprotein (MSAFP) screening for Down syndrome in women age 35 and older. 8th International Congress for Human Genetics, *Am J Hum Genet*, 49(Suppl):229, 1991.
39. Simpson JL, Palomaki GE, Elias S, Haddow JE, Andersen R, Brownlee M: Correlation between second and third trimester maternal serum alpha fetoprotein (MSAFP). Society for Gynecologic Investigation, 1991.
40. Rose NC, Palomaki GE, Knight GJ, Pulkkinen A, Haddow JE, Donnenfeld AE, Cohen AW, Mennuti MT: Second trimester diurnal variation of MSAFP, hCG, and uE3: Is it present and does it effect prediction of a patient's risk for fetal Down syndrome? Clinical and Molecular Cytogenetics of Developmental Disorders Conference, July 1992.
41. Haddow JE, Palomaki GE, Knight GJ, Cunningham GC, Lustig L, Boyd P: Prenatal screening to reduce the need for amniocentesis in women age 35 and older. *Am J Hum Genet*, 53:a4, 1993.
42. Haddow JE, Palomaki GE, Knight GJ: First trimester screening for Down syndrome using biochemical and ultrasound markers. *Am J Hum Genet*, 59:A41, 1996.
43. Miller WA, Nee H, Hayes A, Crawford D, Johnson A, Haddow JE: Interpretation of molecular testing in low risk pregnancies: A counseling dilemma. *Am J Hum Genet*, 59:A170, 1996.

44. Palomaki GE, Knight GJ, Fodor KK, Haddow JE: Second trimester screening performance of free b-subunit versus hCG on a population with complete ascertainment of Down syndrome. *Am J Hum Genet*, 59:A327, 1996.
45. Palomaki GE, Neveux LM, Knight GJ, Haddow JE: Maternal weight and first trimester Down syndrome screening. *Am J Hum Genet*, 61:A160, 1997.
46. Palomaki GE, Bradley LA, Doherty RA, Haddow JE: Prenatal screening for cystic fibrosis (CF): Is it cost effective for all racial/ethnic groups? *Am J Hum Genet*, 61:A19 1997.
47. Palomaki GE, Bradley LA, Richards CS, Grody WW, Stenzel TT, Haddow JE: Estimating analytic validity for *HFE* Testing in the General Population. American College of Medical Genetics, San Diego, CA, March, 2003.
48. Palomaki GE, FitzSimmons SC, Bradley LA, Haddow JE: Prenatal screening for cystic fibrosis: Clinical validity in the selected racial/ethnic groups. American College of Medical Genetics, San Diego, CA, March, 2003.
49. Bradley LA, Palomaki GE, Hyman D, Richards CS, Haddow JE: Prenatal cystic fibrosis (CF) screening: barrier to demonstrating clinical validity and utility in practice. American College of Medical Genetics, San Diego, CA, March, 2003.
50. Palomaki GE, Grosse SD, Haddow JE: The financial cost of prenatal screening for cystic fibrosis in the United States. American College of Medical Genetics, San Diego, CA, March, 2003.
51. Palomaki GE, Haddow JE, Knight GJ: Within-person variability of TSH, free T4, and TPO antibodies between the first and second trimesters in viable pregnancies. Scientific Workshop on Maternal Thyroid Disease. Centers for Disease Control, Atlanta, Ga. January 12-13, 2004.
52. Craig, WY, Palomaki GE, Neveux LM, Haddow JE: High Second Trimester Body Mass Index and Offspring Neurocognitive Development. Annual meeting of the Endocrine Society, San Francisco, CA, June 17, 2013

PEER-REVIEWED

1. DNA Testing Standards: The ACCE Project, a model system to assess the availability, quality, and usefulness of existing data on DNA-based tests and testing algorithms. www.fbr.org/research/acce-cdc/cdcacce-dd.html and www.cdc.gov/genomics/info/reports/research/FBR/ACCE.htm

INVITED PRESENTATIONS (representative partial list):

1. Haddow JE: A projected analysis of costs in the Maine neural tube defect screening program. First Scarborough Conference on Screening for Neural Tube Defects in the United States (Scarborough, Maine), September 6-8, 1977.
2. Haddow JE: A pilot project aimed at developing statewide neural tube defect screening in Maine. First Scarborough Conference on Screening for Neural Tube Defects in the United States (Scarborough, Maine), September 6-8, 1977.
3. Haddow JE: Informed consent and patient education. First Scarborough Conference on Screening for Neural Tube Defects in the United States (Scarborough, Maine), September 6-8, 1977.
4. Haddow JE: Amniotic fluid proteins in relation to low birthweight/prematurity. Second Scarborough Conference on Screening for Neural Tube Defects in the United States (Scarborough, Maine), September 5-7, 1978.
5. Haddow JE: Cotinine measurements to study people's smoking habits. Fourth Scarborough Conference on Preventive Medicine (Scarborough, Maine), September 15-17, 1984.
6. Haddow JE: The WHO position. Fourth Scarborough Conference on Preventive Medicine (Scarborough, Maine), September 15-17, 1984.
7. Haddow JE: Serum cotinine as a marker of cigarette smoking during pregnancy. New England Pediatric Society Meeting (Scarborough, Maine), June 23, 1984.
8. Haddow JE: Biochemical epidemiology as applied to assessing pregnancy risk. University of Vermont, Department of Pediatrics (Burlington), October 17, 1984.
9. Haddow JE: Biochemical markers to assess passive smoking. Invited presentation to National Academy of Science (Washington, D.C.), October 4, 1985.

10. Haddow JE: Numbers of cigarettes smoked, serum cotinine, and birthweight. Seminar, Department of Environmental & Preventive Medicine, Medical School of St. Bartholomew's Hospital (London), April 28, 1985.
11. Haddow JE: Prenatal screening for Down syndrome. Invited presentation to Dartmouth Hitchcock Medical Center, May 28-29, 1986.
12. Haddow JE: Disorders of brain development and cognition: Prevention of mental retardation. Harvard Postgraduate Course, May, 1988.
13. Haddow JE: Experience from the ACCE Project. Workshop, Public Health Assessment of Genetic Testing. Centers for Disease Control, Atlanta, Georgia. February 28, 2003.
14. Haddow JE: Short Course, Essentials of Prenatal Screening. Foundation for Blood Research, Scarborough, Maine. Annual presentations, 1985-2005. Presenter of the following at the 2005 course, September 11-15, 2005:
 - Major defects identified by open neural tube defect (ONTD) screening
 - The effect of ultrasound on ONTD screening
 - Morbidity and mortality associated with Down syndrome
 - Impact of Down syndrome screening on birth prevalence
 - Undetectable estriol levels, including SLOS
15. Haddow JE: Criteria for screening. Scientific Workshop on Maternal Thyroid Disease. Centers for Disease Control, Atlanta, Georgia, January 12-13, 2004.
16. Haddow JE: Intensive Short Course on Down's Syndrome Screening, Wolfson Institute of Preventive Medicine, London, England, annually 1991-2011. Presenter of the following:
 - What is screening?
 - Other aneuploidies in Down's syndrome screening programmes (including Trisomy 18)
 - Very low uE3 including Smith Lemli Opitz syndrome
 - Screening for hypothyroidism in pregnancy
 - Screening programme aspects
17. Haddow JE: Disorder/setting: a cornerstone for ACCE evaluation. Public Health Assessment of Genetic Tests for Screening & Prevention. Office of Genomics and Disease Prevention. Centers for Disease Control (CDC) and Foundation for Blood Research, Atlanta Georgia. September 27-28, 2004.
18. Haddow JE: The US pilot trial on integrated serum screening. Wolfson Institute for Preventive Medicine. London, England, October 7, 2004.
19. Haddow JE: Components of Evaluation. Describing the Disorder, Test, and Setting. Expert Meeting on Evidence-Based Review of Genomic Applications. Westin Peachtree Plaza Hotel, Atlanta, GA, January 24-25, 2005.
20. Haddow JE: Public Health Assessment of Genetic Tests for Screening and Prevention. 24th Annual Education Conference. National Society of Genetic Counselors, Inc. The Westin Century Plaza Hotel, Los Angeles, CA, November 12, 2005.
21. Haddow JE: Hypothyroidism. Postgraduate Course: Human Teratogens, Harvard Medical School, Department of Continuing Education, Boston, MA, April 2-4, 2006.
22. Haddow, JE: Thyroid Hormone and Public Health. The Teratology Society, Loews Ventana Canyon Resort, Tucson, AZ, June 24-29, 2006.
23. Haddow JE: Short Course, Essentials of Prenatal Screening. Women & Infants Hospital, Providence, Rhode Island. Presenter of the following at the 2006 course, September 17-20, 2006:
 - Major defects identified by open neural tube defect (ONTD) screening
 - The effect of ultrasound on ONTD screening
 - Morbidity and mortality associated with Down syndrome
 - Impact of Down syndrome screening on birth prevalence
 - Undetectable estriol levels, including SLOS
24. Haddow JE: Short Course, Essentials of Prenatal Screening. Women & Infants Hospital, Providence, Rhode Island. Presenter of the following at the 2007 course, October 11-14, 2007:
 - Major defects identified by open neural tube defect (ONTD) screening
 - The effect of ultrasound on ONTD screening
 - Morbidity and mortality associated with Down syndrome

Impact of Down syndrome screening on birth prevalence
Undetectable estriol levels, including SLOS

25. James Haddow, M.D. attended the EGAPP Working Group meeting at the CDC September 30-October 1, 2008, in Atlanta, Georgia.
26. Haddow JE: Short Course, Essentials of Prenatal Screening. Women & Infants Hospital, Providence, Rhode Island. Presenter of the following at the 2009 course, April 3-6, 2009:
 - Major defects identified by open neural tube defect (ONTD) screening
 - The effect of ultrasound on ONTD screening
 - Morbidity and mortality associated with Down syndrome
 - Impact of Down syndrome screening on birth prevalence
 - Undetectable estriol levels, including SLOS
27. James Haddow, M.D. attended the EGAPP Working Group meeting at the CDC February 2-3, 2009, in Atlanta, Georgia.
28. James Haddow, M.D. attended Short Course, Essentials of Prenatal Screening. Women & Infants Hospital, Providence, Rhode Island. Presenter of the following at the 2009 course, April 3-6, 2009: Major defects identified by open neural tube defect (ONTD) screening; The effect of ultrasound on ONTD screening; Morbidity and mortality associated with Down syndrome; Impact of Down syndrome screening on birth prevalence; Undetectable estriol levels, including SLOS.
29. James Haddow, M.D. presented the talk entitled: *Impact of Maternal and Fetal Hypothyroidism on Child IQ and Other Development (Including Timing During Gestation)*, at the American Thyroid Association 2009 Spring Symposium: Thyroid Dysfunction and Pregnancy: Miscarriage, Preterm Delivery and Decreased IQ. Washington, DC., April 17, 2009.
30. James Haddow, M.D., presented the talk entitled: *Thyroid Deficiency. Human Teratogens: Environmental Factors Which Cause Birth Defects*. Offered by the Mass General Hospital. April 26, 2009.
31. James Haddow, M.D., attended the Intensive Short Course on Down's Syndrome Screening, Wolfson Institute of Preventive Medicine, London, England, May 2009. He presented the following: What is screening? Other aneuploidies in Down's syndrome screening programmes (including Trisomy 18). Very low uE3 including Smith Lemli Opitz syndrome. Screening for hypothyroidism in pregnancy. Screening programme aspects.
32. James Haddow, M.D. attended the EGAPP Working Group meeting at the CDC June 15-16, 2009, in Atlanta, Georgia.
36. James E. Haddow, M.D. attended the NIH State-of-the-Science Conference on Family History and Improving Health, August 24-26, 2009 in Bethesda, Maryland. He presented a talk entitled: *"The Potential Costs of Screening for Risk with Family History"*.
37. Haddow JE: Short Course, Essentials of Prenatal Screening. Women & Infants Hospital, Portland, Maine. Presenter of the following at the 2010 course, March 19-22, 2010:
 - Major defects identified by open neural tube defect (ONTD) screening
 - The effect of ultrasound on ONTD screening
 - Morbidity and mortality associated with Down syndrome
 - Impact of Down syndrome screening on birth prevalence
 - Undetectable estriol levels, including SLOS
38. Haddow JE: Short Course, Essentials of Prenatal Screening. Women & Infants Hospital, Portland, Maine. Presenter of the following at the 2011 course, September 23-26, 2011:
 - Major defects identified by open neural tube defect (ONTD) screening
 - The effect of ultrasound on ONTD screening
 - Morbidity and mortality associated with Down syndrome
 - Impact of Down syndrome screening on birth prevalence
 - Undetectable estriol levels, including SLOS

38. Haddow JE: Short Course, Essentials of Prenatal Screening. Women & Infants Hospital, Portland, Maine. Presenter of the following at the 2012 course, September 7-10, 2012:
 - Major defects identified by open neural tube defect (ONTD) screening
 - The effect of ultrasound on ONTD screening
 - Morbidity and mortality associated with Down syndrome
 - Impact of Down syndrome screening on birth prevalence
 - Undetectable estriol levels, including SLOS
39. Haddow JE: Intensive Short Course on Down's Syndrome Screening, Wolfson Institute of Preventive Medicine, London, England, May 20-22, 2013. Presenter of the following:
 - Key points in screening?
 - The detection of other fetal abnormalities in Down's syndrome screening programmes
 - Bringing in the new technology: the importance of a population based strategy
40. Haddow JE: Short Course, Essentials of Prenatal Screening. Women & Infants Hospital, Portland, Maine. Presenter of the following at the 2014 course, April 6-9, 2014:
 - Background and Introduction
 - Principles of Screening I
 - Major Defects Identified by ONTD Screening
 - Morbidity and Mortality: Down syndrome, T18/13
 - Morbidity and Mortality: Sex Aneuploidies
41. Haddow JE: Wolfson Institute Intensive Course, London, England, May 19-20, 2015.
 - Medical Screening: Definition and Checklist
 - Is there a justification for antenatal screening for sex chromosome aneuploidies?
 - Who is driving the application of DNA testing?

GRANTS:

1. Project Title: Reducing Mercury Toxicity with Spironolactone
 - Funding Agency: Hood Foundation
 - Funding Amount: \$25,000
 - Dates: 1970-1971
 - PI: James E. Haddow, M.D.
2. Project Title: Counseling and Testing for Neural Tube Defects
 - Funding Agency: Developmental Disabilities Council, State of Maine
 - Funding Amount: \$36,000
 - Dates: 10/76-9/80
 - PI: James E. Haddow, M.D.
3. Project Title: Intervention to Reduce Smoking During Pregnancy
 - Funding Agency: National Institute of Child Health and Human Development, NIH
 - Funding Amount: \$333,833
 - Dates: 2/1/1984 - 1/31/1988
 - PI: James E. Haddow, M.D.
4. Project Title: Prenatal Screening to Reduce Amniocentesis over Age 35
 - Funding Agency: Maternal/Child Health Bureau, US Department of Health and Human Services
 - Funding Amount: \$904,473
 - Dates: 6/1/90-5/31/92
 - PI: James E. Haddow, M.D.
5. Project Title: First Trimester Prenatal Screening for Down Syndrome
 - Funding Agency: National Institute of Child Health and Human Development, NIH
 - Funding Amount: \$1,010,525
 - Dates: 12/1/93-11/30/96
 - PI: James E. Haddow, M.D.

6. Project Title: DNA and Biochemical Markers of Hemochromatosis
Funding Agency: Davis Family Foundation
Funding Amount: \$12,500
Dates: 1997
PI: James Haddow, M.D.
7. Project Title: Development of Guidelines for Validation of Genetic Tests
Funding Agency: Massachusetts Health Research Institute (MHRI)
Funding Amount: \$17,194
Dates: 10/1/96-9/30/97
PI: James Haddow, M.D.
8. Project Title: Is Maternal Hypothyroidism Associated with Low IQ in Offspring?
Funding Agency: Thrasher Research Fund
Funding Amount: \$100,835
Dates: 10/1/95 - 9/30/97
PI: James E. Haddow, M.D.
9. Project Title: Is Maternal Hypothyroidism Associated with Low IQ in Offspring?
Funding Agency: Knoll Pharmaceutical Company
Funding Amount: \$100,000
Dates: 10/1/95-9/30/97
PI: James E. Haddow, M.D.
10. Project Title: Is Maternal Hypothyroidism Associated with Low IQ in Offspring?
Funding Agency: Knoll Pharmaceutical Company
Funding Amount: \$12,650
Dates: 1997
PI: James E. Haddow, M.D.
11. Project Title: Delivery of Genetic Services in Maine - Enhancing the Role of PCP
Funding Agency: Maternal/Child Health Bureau, US Department of Health and Human Services
Funding Amount: \$392,000
Dates: 10/1/94-9/30/97
PI: James E. Haddow, M.D.
12. Project Title: Epidemiologic Approach to EHS in High School Biology
Funding Agency: National Center for Research Resources, NIH
Funding Amount: \$328,672
Dates: 10/1/97-9/30/00
PI: James E. Haddow, M.D.
13. Project Title: Developing Processes for Evaluating DNA Tests
Funding Agency: Centers for Disease Control and Prevention
Funding Amount: \$766,134
Dates: 9/30/00-9/29/04
PI: James E. Haddow, M.D.
14. Project Title: Hepatocellular Carcinoma and Hemochromatosis
Funding Agency: Centers for Disease Control and Prevention
Funding Amount: \$63,500
Dates: 2003
PI: James E. Haddow
15. Project Title: Are IQs Low in Offspring of Euthyroid Women with Low T4?
Funding Agency: National Institute of Child Health and Human Development, NIH
Funding Amount: \$1,194,750
Dates: 2/1/04-1/31/09
PI: James E. Haddow, M.D.

16. Project Title: Feasibility of Prenatal Screening for SLO Syndrome
 Funding Agency: National Institute of Child Health and Human Development, NIH
 Funding Amount: \$4,392,769
 Dates: 4/1/00-3/31/05
 PI: James E. Haddow, M.D.
17. A Model Statewide Trial to Detect and Treat Maternal Hypothyroidism in Pregnancy
 Funding Agency: Centers for Disease Control and Prevention
 Funding Amount: \$1,349,904
 Dates: 4/1/08-3/31/11
 PI: James E. Haddow, M.D.

UNIVERSITY TEACHING ROLES: N/A

HOSPITAL TEACHING ROLES:

- 1966-1974 Supervised training of Pediatric Residents on rotation through the Clinical Research Unit of Boston City Hospital and led ward rounds for 3 months/year.
- 1970-1974 Director, Medical Student Teaching in Pediatrics, Boston University School of Medicine. Duties included supervising and participating in formal teaching of an average of 10 fourth year medical students/month at Boston City Hospital and giving lectures to first and second year medical students at Boston University Medical School. Hospital teaching of students and house staff involved endocrinology and metabolism with emphasis on fluid and electrolyte balance. Medical School teaching focused on inherited errors of metabolism such as PKU.
- 1974-1980 Supervised clinical research projects for selected residents in Pediatrics and Medicine at Maine Medical Center.

Postgraduate training support. As part of TDR's efforts to increase the capacity of LMICs to undertake a leadership role in research on the control of infectious diseases of poverty, we provide training grants with a focus on implementation research. Support for postgraduate training is a TDR core area of work. In 2015, the TDR postgraduate training scheme evolved from a focus on individuals to a partnership with seven universities in LMICs, selected by an external committee of public health experts. Divisions > General Surgery > Education > Postgraduate Training Programs. Back to Top. Postgraduate Training Programs. Resources. McMaster University Postgraduate Programs are integrated in cooperation with the affiliated teaching hospitals and therefore there is no primary base hospital. We provide access to electronic medical resources for residents at all hospitals. A postgraduate diploma, postgraduate degree or Master's degree offers the student an advanced level of education in their chosen area of study. The course content is designed to build on the knowledge obtained at undergraduate degree level. Often the course content is more practical in nature to better prepare the student with the skills they will need in the workplace. Completing postgraduate studies helps students further their career prospects and deepen their understanding of their area of study.